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Summary
Objectives - To evaluate clinical criteria to diagnose Alzheimer’s disease and to 
describe the epidemiology of presenile Alzheimer’s disease in Scotland from 1974 
to 1988.
Design - Retrospective review of hospital records of patients aged less than 73 years 
admitted to psychiatric hospital with various diagnoses of dementia. Diagnoses 
were classified by National Institute of Communicative Disorders and Stroke and 
the A lzheimer’s Disease and Related Disorders Association Criteria (NINCDS- 
ADRDA) and the Hachinski score. Accuracy of diagnosis was assessed by 
reference to the neuropathological diagnosis in those who underwent postmortem 
examination. Completeness of the study sample was evaluated by scrutiny of 
selected neurology outpatient and general hospital records.
Setting - All general psychiatric hospitals in Scotland.
Subjects - All patients with onset of dementia aged 40 - 64 years inclusive.
Main outcome measures - Probable, broad and definite Alzheimer’s disease, sex of 
patient, age at onset, age at presentation, date of death, place of death.
Results - 5874 psychiatric hospital records, 129 neurology outpatient records, 89 
records from non-psychiatric hospitals and 61 neuropathology records were 
examined. A discriminant function analysis, which entered the clinical criteria as 
variables, was performed and the diagnostic accuracy of the clinical criteria was 
compared before and after the analysis. NINCDS-ADRDA criteria had a diagnostic
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accuracy of 72% (specificity 88%, sensitivity 61%) compared to 77% (specificity 
80%, sensitivity 75%) after analysis. NINCDS-ADRDA criteria together with a 
Hachinski score had an accuracy of 72% (specificity 61%, sensitivity 88%) 
compared to 83.6% (specificity 76%, sensitivity 89%) after analysis. Variables of 
highest discriminating value were the Hachinski score, presence of coexistent 
neurological disease and presence of coexistent systemic disease.
317 patients met criteria for probable Alzheimer’s disease and 569 met 
criteria for broad Alzheimer’s disease. Minimal incidences per 100 000 population 
aged 60-64 years were 22.6 (95% confidence interval, 20.2 to 25.2) and 40.5 (38.9 
to 42.3) per 100 000 for probable and broad Alzheim er’s disease. In the 1981 
census year the annual incidence of probable A lzheim er’s disease was 1.6 (1.0 to 
2.6). Female gender was associated with a higher incidence of probable and broad 
Alzheimer’s disease.
The five year survival rate for probable Alzheimer’s disease was 51.2% 
decreasing to 17.3% at ten years. Females survived 1.3 times longer than males 
(95% confidence interval 1.04 to 1.61). Place of death, age at presentation and year 
of presentation did not significantly affect survival duration. There was no evidence 
of increased survival in those patients with probable Alzheimer’s disease over the 
time period from 1974 to 1988.
Conclusions - Current clinical criteria used to diagnose Alzheimer’s disease are 
limited and can be substantially improved. Female gender is positively associated 
with the development of Alzheimer’s disease before age 65 years. Female patients 
with a clinical diagnosis of probable Alzheimer’s disease live longer than male 
patients with the same diagnosis.
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Section 1: Literature review
The literature on Alzheimer's disease is vast and the following review is 
necessarily selective but acts as an introduction to the original work reported. The 
review concentrates on three main areas which are most relevant to the thesis.
Firstly, practical methodological considerations of disease definition and study 
sample choice will be discussed. Secondly, the basic epidemography of Alzheimer's 
disease will be described. Finally, the aetiology of the illness will be reviewed with 
known and proposed risk factors detailed.
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DEFINITION OF ALZHEIMER’S DISEASE
The paucity of consistent epidemiology data on Alzheimer’s disease is 
largely explicable by difficulty in its antemortem diagnosis. The definition of 
A lzheimer’s disease as a clinical, neuropathological or neurochemical entity is 
complex and controversial. However, a valid definition is a prerequisite for research 
in the illness and, therefore, a logical starting point in a review of the literature.
(a) Clinical definition of Alzheimer’s disease.
The clinical diagnosis of Alzheimer’s disease remains presumptive until 
confirmed by neuropathological examination. Definite Alzheimer's disease is a 
neuropathological diagnosis requiring the demonstration of specific 
neurohistological features (McKhann et al, 1984), but no universally accepted 
neuropathological criteria for this diagnosis exist (Khachaturian, 1985,Tierney et al,
1988). There are two further concerns. Firstly, in clinical practice and medical 
research neuropathological validation of diagnosis is rarely possible because 
cerebral biopsy in the absence of an effective treatment is considered unethical. 
Secondly, neurohistological features of the disease can be present in clinically 
nondemented elderly people. This diagnostic difficulty has important repercussions 
and it was not uncommon for clinical diagnostic error rates in Alzheimer's disease 
research to approach 50 percent (Garcia et al, 1981). Uniform clinical diagnostic 
criteria for the disease are needed and several have been proposed.
To facilitate epidemiological research, clinical criteria have been described to 
define the illness. Two comparable, but broad, definitions for Alzheimer’s disease 
have been accepted (DSM-1II-R and ICD 9) and several compatible clinical criteria 
described (Eisdorferand Cohen, 1980, McKhann et al, 1984). Of these, clinical
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criteria proposed by the Work Group of the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer's Disease Association 
(NINCDS-ADRDA) to diagnose possible, probable and definite A lzheimer’s 
disease have been readily accepted (McKhann et al, 1984). The criteria for probable 
Alzheimer’s disease are widely used in therapeutic and epidemiological research to 
define the disease in study populations. They have been validated in 
neuropathological studies and consistently have a diagnostic accuracy rate over 80% 
(Bums et al, 1990, Martin et al, 1987). However, the results of these studies are 
flawed because investigators rarely report neuropathological criteria used to define 
Alzheimer's disease and, importantly, their interpretation of the clinical criteria 
(Tierney et al, 1988). The clinical criteria are subjective, flexible, subject to 
interobserver variation and are not unambiguously defined (Kukull 1990(a and b)). 
The Work Group suggested that the criteria were tentative and could be improved by 
critical examination.
(b) Neuropathology of Alzheimer’s disease.
There have been advances in understanding the neuropathology of 
Alzheimer's disease, particularly at a neurohistological and a neurochemical level. 
The neuropathological changes in Alzheimer's disease overlap with 
neurophysiological ageing processes. This causes difficulty in reaching a 
consensus as to what constitutes ‘definite’ Alzheimer’s disease. Neurohistological 
and neurochemical changes considered characteristic of Alzheimer's disease are 
presented.
(i) Neurohistology.
In 1906 Alois Alzheimer reported his observations on a 51 year old woman 
who was at the insane asylum in Frankfurt Main (Alzheimer A, 1906). At post­
mortem, he described her atrophic brain without macroscopic abnormality.
13 Alzheimer's disease in Scotland
Microscopically neurofibrils, neuronal death and miliary foci were reported scattered 
throughout the entire cortex. Arteriosclerotic changes in large blood vessels and 
neovascularisation were also recorded. Since then the presence of a distinct disease 
process has been broadly accepted, though the degree of neuropathological change 
(along with clinical features) necessary to confirm its existence is debated.
Morphological changes of cerebral atrophy, neuronal cell loss, 
neurofibrillary tangles and neuritic plaques are established features of Alzheimer's 
disease (Terry and Katzman, 1983, Brun, 1985). Neurofibrillary tangles arise within 
neurones as submicroscopic filamentus structures wound round each other as a 
"paired helical filament" (Crowther and Wischik, 1985). Neuritic or senile plaques 
comprise degenerating nerve terminals with amyloid protein and aluminosilicate at 
their core (paired helical filaments can also accumulate in these plaques)
(Wisniewski and Terry, 1970, Katzman, 1986, Candy et al 1986). Cerebrovascular 
amyloid within blood vessels in the meninges, cerebral cortex and hippocampus and 
granulovacuolar inclusion bodies, particularly in hippocampal neurones, are 
recognised neurohistological features of A lzheimer’s disease (Vinters and Gilbert 
1983, Ball, 1977, Ball et al, 1983). The topography of all these lesions is not strict 
nor pathognomonic of the disease (Ulrich and Stahelin, 1984, Tomlinson et al,
1968).
The result is that no standard inclusion neuropathological criteria to 
diagnose definite Alzheimer's disease have been accepted. It is accepted that 
exclusion criteria for vascular dementia are required before the diagnosis of definite 
Alzheimer's disease can be reached, but again no criteria can be agreed (Tierney et al, 
1988, Tomlinson et al, 1970, Molsa et al 1985). Such lack of agreement adversely 
affects clinical research. The diagnostic accuracy of clinical criteria may vary by 
approximately 10% depending on the neuropathological criteria used to confirm 
Alzheimer's disease (Tierney et al, 1988).
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(ii) Neurochemistry.
The brains of people with Alzheimer's disease have a 40 - 90 percent 
decrease in activity of acetylcholine associated enzyme and choline acetyltransferase, 
ACE and CAT, in the cerebral cortex and hippocampus (Davies and Maloney, 1976, 
White et al, 1977). This deficit correlates with neuropathological changes and 
severity of dementia and is demonstrable in the first year of symptoms (Perry et al, 
1978, Katzman, 1986). It is largely due to a loss of primary ascending presynaptic 
cholinergic neurones, but there is also a smaller loss of muscarinic postsynaptic M2 
receptors (Davies and Verth, 1977, Mash et al, 1985).
This discovery led to the cholinergic hypothesis to explain memory 
impairment in Alzheimer's disease. The hypothesis postulated a connection between 
some of the cognitive impairments of the disease, especially memory, and a 
disturbance in presynaptic cholinergic transmission (Davidson, 1979, Perry, 1986). 
It could have heralded a treatment or even cure for the disease. However, although 
the cholinergic hypothesis has generally stood the test of time it has not led (so far) 
to an effective treatment (Perry, 1991). This is because the complete effects and 
interactions of the cholinergic system within the brain are more complex than 
originally thought. For example, trophic factors (e.g. nerve growth factor) maintain 
forebrain cholinergic neurones and can even 'rescue' them in ageing animal brains 
(Perry, 1990, Stromberg et al, 1990). Also, cholinergic deficits are not specific to 
Alzheimer’s disease and have been described in physiological ageing and 
Parkinson's disease (McGeer et al, 1984, Perry, 1990(b)).
Other neurochemical changes are a feature of Alzheimer's disease, for 
example, a decrease in the concentration of cortical somatostatin, a peptide 
neurotransmitter (Davies et al, 1980, Rossor et al 1980, Arai et al, 1984). Other less 
consistent deficits have also been reported in Alzheimer disease, such as decreases 
in noradrenaline and serotonin levels within the brain but increased levels of
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noradrenaline and its metabolites in the cerebrospinal fluid around the brain (Arai et 
al 1984, Raskind et al, 1984).
Summary.
Alzheimer's disease is a distinct pathological illness, however, its boundaries 
in terms of clinical features, neurohistological features and neurochemical changes 
merge with those physiological changes experienced with age. There are no 
pathognomonic features of Alzheimer’s disease and this causes diagnostic 
difficulties which impedes epidemiological research. Improving clinical criteria to 
diagnose A lzheimer’s disease for specific use in epidemiological research is a major 
objective of this thesis.
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SAMPLING AND STUDY DESIGNS
Population sampling is a major concern which limits conclusions drawn 
from epidemiological research in Alzheimer’s disease (Weiler, 1986). This arises 
because of the insidious nature of the illness and the variety of ways in which it can 
present to medical attention. This review critically appraises the main advantages 
and disadvantages of study designs used in previous epidemiological studies in 
Alzheimer’s disease.
(a) Study samples.
(i) Community-based studies in Alzheimer’s disease.
All, or a randomly chosen sample of people, within a defined geographical 
area have been studied (Rocca et al, 1990, Evans et al, 1989, Pfeffer et al, 1987). 
Typically, after screening for cognitive impairment in a geographically defined 
population, a sample that has possible dementia is ascertained and all, or a further 
random sub-sample, is studied. The main advantages and disadvantages of this 
selection process are outlined in Table A.
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Table A. Main advantages and disadvantages o f  com m unity-based  
screening for A lzh e im er 's  disease.
A D V A N TA G ES D ISA D V A N TA G ES
Useful in assessing local health care 
needs
Validity and reliability o f  screening test 
(? miss asym ptom atic  and mild cases)
D emographic data directly applicable Large nu m b er  o f people need to be 
screened
Sam ple less dependent on availability of 
health care
People with dementia m ay be 
preferentially missed in survey
The use o f  com m unity  based studies within localised, defined geographical 
regions to investigate possible associations between environmental toxin exposure 
and the developm ent o f  A lzheim er's  disease are potentially flawed. Bias is 
introduced when conclusions drawn from small geographical ares are extrapolated 
to national populations if the effects of population migration, temporal and 
geographical variation in risk exposure, validity o f  diagnostic criteria or dynam ic 
changes in health care.provision have not been considered as plausible explanations 
o f results. Selection bias and difficulty generalis ing  conclusions beyond the study 
area are m ajor problem s in com m unity-based  research.
(ii) Health service studies in A lzh e im er 's  disease
Hospital in-patients (Erkinjuntti et al, 1986, G agnon et al, 1988), out-patients 
(Broe et al, 1990, Shalat et al, 1987. W alsh et al, 1990), patients w ho attend specialist 
m em ory  clinics (Philpot et al, 1989. Hier et al. 1989) and com binations of all these
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sources (Hofm an et al. 1989. Schoenberg et al, 1987. Traves et al. 1986) have been 
used as study sam ples in epidemiological research in Alzheim er's  disease. T he main 
advantages and disadvantages are shown in Table B.
T able B. Main advantages and disadvantages o f  study samples derived from 
hospital services.
A D V A NTA G ES D ISA D V A N TA G ES
Retrospective data available Selection bias; asym ptom atic  cases, mild 
cases and m isd iagnosed  cases missed.
Large num bers o f sufferers can be 
identified quickly and cheaply
Dem ographic data not directly 
applicable
Useful in hospital service planning Sample determined by availability of 
health services
Selection bias remains a cause for concern. U ndiagnosed and misclassified 
people w ith A lzh e im er 's  disease w ill be excluded from study. The num ber o f  such 
people may not be random, but reflect variations in local availability o f  health care.
(iii) M iscellaneous study sam ples in A lzh e im er 's  disease.
A variety o f other sampling sources have been used in epidemiological 
research in A lzhe im er 's  disease. For examples, radiological (Martyn et al, 1988) 
and neuropathological records (W halley and Holloway. 1985) have identified 
subjects for study. Both these sources have been widely criticised because of 
concerns about selection bias. The availability o f CT scanners varies widely in and 
between geographical areas and people who have this investigation cannot be
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considered representative of sufferers with Alzheimer’s disease (Ebrahim, 1989, 
Schupf et al, 1989). The main use of post-mortem based studies in epidemiological 
research is to assess the validity of clinical criteria in the ante-mortem diagnosis of 
Alzheimer's disease (Boiler et al, 1989, Risse et al, 1990).
Regional diagnostic registries of patients with Alzheimer's disease have also 
been used (Still et al, 1990). Problems arise in relation to the completeness and 
availability of these diagnostic registries and their validity remains to be established 
(Hughes et al, 1989).
(b) General limits imposed in studies in Alzheimer’s disease.
General limitations are imposed on populations to find most efficiently those 
people with Alzheimer's disease. The limits are dictated by the study hypothesis, the 
time available to complete the study, ethical considerations and by available 
resources.
(i) Arbitrary age limits are a common and effective way of increasing the 
efficiency of study sampling. For example, all people aged more than 58 years 
(Rocca et al, 1990), 59 years (Philpot et al, 1989) and 64 years (Walsh et al, 1990) 
have constituted study populations. Similarly, age ranges have been imposed 
(Brayne and Calloway, 1989).
(ii) Time limits have been set. For example, patients with Alzheimer's 
disease between 1960 to 1964 (Schoenberg et al, 1987) and between 1980 to 1988 
(Hofman et al, 1989) have been studied in defined communities. Time limits should 
allow ascertainment of sufficient numbers of people with Alzheimer's disease to test 
the study hypothesis and permit the application of demographic data accumulated 
through census or social studies.
(iii) Residential limits are rarely imposed, although the effects of migration 
within a population may be profound. Some studies have attempted to monitor the
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residential stability of the population. For example, people have needed to be 
resident in study areas for at least one year (Schoenberg et al, 1987) or ten years 
(Whalley and Holloway, 1985) to be accepted for analysis.
(iv) Other limitations are rarely imposed but have included gender (Shalat et 
al, 1987) and racial limits (Treves et al, 1986).
(c) Specific limits imposed in studies in Alzheimer’s disease.
Specific limitations are imposed by the investigator to define Alzheimer's 
disease in the population. The limits are dictated by the natural history of the 
disease and reflect the difficulty in establishing the diagnosis and the time of 
symptom onset in individuals with the disease. The importance of clinical 
diagnostic criteria has already been discussed (Chapter - Definition of Alzheimer's 
disease).
Onset of symptoms and date of presentation to medical care are different in 
Alzheimer's disease (Hier et al, 1989, McGonigal et al, 1992). In prevalence studies 
the presence of symptoms of Alzheimer's disease at a fixed time point is sufficient 
(Zhang et al, 1990, Rocca et al, 1990). In other epidemiological studies, specific 
limits are imposed to define disease onset and age patients so that general limits can 
be applied.
Date of first presentation to medical care with symptoms of dementia has 
been used to age Alzheimer patients (Hofman et al, 1989). This date is discrete, 
objective and readily available from hospital records. However, the date is 
dependent on referral patterns of patient to primary care physician and of primary 
care physician to hospital, which could cause non-random selection bias. Also, a 
large proportion of the coarse of the disease is from time of symptoms to 
presentation and will be excluded from study (Walsh et al, 1990, McGonigal et al, 
1992).
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Date of onset of symptoms of Alzheimer's disease has been used to age 
patients (Schoenberg et al, 1987, Ferini-Strambi et al, 1990). This date is less 
dependent on referral patterns and assesses the entire clinical course of the illness. 
Disadvantages relate to the insidious onset of Alzheimer's disease. This date is not 
discrete, is subject to recall error and may not be known. Criteria to define the date 
can have a critical influence on patient ascertainment (Breitner and Magruder-Habib,
1989).
Summary.
The population chosen for epidemiological research in Alzheimer's disease 
is dependent on the study hypothesis, financial and ethical concerns. Many sources 
have been used to generate study samples. No population sample is ideal when 
compared to studying an entire population, but this is rarely practical. Investigators 
must appreciate the limitations of population sampling and reasonably exclude 
sampling bias as an explanation of findings. W hat is considered ‘reasonable’ must 
be decided by colleagues and will be, in part, dependent on the gravity of the study’s 
conclusions. For example, I suggest that for environmental exposure to aluminium 
to be accepted as a risk factor for Alzheimer’s disease will require convincing 
evidence because of the economic and social impact of such a conclusion.
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EPIDEMIOLOGY OIF ALZHEIMER'S DIESASE
Alzheimer's disease presents a considerable challenge to society and the 
National Health Service in terms of cairing for sufferers and relatives and in the cost 
of providing such care. Its importance; in public health terms has substantially 
increased this century for a variety of reasons. Improved life expectancy coupled 
with demographic changes in the age structure of the population mean that more 
people are living to old age and developing dementing illnesses. Similarly, new 
treatments are improving the prognosis for previously chronic fatal illnesses, (e.g 
chronic renal failure), such that more s,ufferers reach old age with the inherent risk 
of dementia ("the failures of success")i.
Epidemiology is the study of tlhe occurence and causes of disease (and 
health) in populations and aims to explain and monitor the distribution of disease in 
communities. It is the science of public health physicians and health service 
planners, providing a rational basis for preventative health policies, future health 
service planning needs, auditing current health care practice, ete.
This chapter reviews measures o f disease frequency (incidence, prevalence 
and survival duration) and examines the effect of gender in Alzheimer's disease. 
Other epidemiological aspects of this illness are detailed elsewhere (associations, 
risk factors, "normal ageing", ete).
(a) Incidence of Alzheimer’s disease.
Incident cases of a disease are those which first occur in a defined time 
period. There is a paucity of good quality, consistent population-based incidence 
data derived from defined communities detailed in the Alzheimer's disease literature 
(Molsa et al, 1982, Treves et al, 1986, Schoenberg et al, 1987). This deficiency is
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important. Incidence rates are of value in defining individual risk of disease, in 
formulating and testing aetiological hypotheses and in planning diagnostic Health 
Service requirements (Morris, 1964). The reasons for this lack of information have 
already been alluded to in the preceeding chapters.
These methodological considerations also explain the wide range of reported 
incidence rates for Alzheimer's disease and undifferented dementia and make direct 
comparisons between different studies hazardous, though not without reward (Table 
C). There are some important, consistent findings reported in these studies.
The incidence rate of Alzheimer's disease and that of undifferentiated 
dementia increases as a function of age in all studies but data at extremes of the 
disease distribution is rare. Information on early onset disease is scarce because 
dementia is rare in this age group (Treves et al, 1986). This deficiency is important 
in testing aetiological hypotheses because early onset cases may have a greater 
exposure to a causative agent and may be more easily identified from routinely 
collected health service returns. Additionally, major advances in understanding the 
genetic nature of early onset Alzheimer's disease cannot be extrapolated to the 
general population unless the basic epidemiology of this aspect of the disease is 
understood.
Data on the incidence rate of disease in the eighth and subsequent decades 
of life is limited by finite human-life span and the size of populations studied.
There has been a suggestion that age-specific incidence rates of Alzheimer's disease 
may decline in later life. If true then those who survive to old age would represent a 
survival elite (Gruenberg, 1977, Jarvik et al, 1980). Current evidence does not 
support this hypothesis with studies reporting a steep rise in incidence rates of 
Alzheimer's and undifferentiated dementia with age (Akesson, 1969, Molsa et al, 
1982, Nilsson, 1984, Hagnell et al, 1983, Rorsman et al, 1986); though the accuracy
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of rates in the older age groups are diminished by small denominators and must be 
interpreted with caution (Molsa et al, 1982, Rorsman et al, 1986).
The inexonerable rise in the incidence of Alzheimer's disease with age would 
suggest that early-onset and late-onset Alzheimer's disease are not uniquely distinct 
pathologies but a continuum of the same disease process (Treves et al, 1986). 
However, I could locate only one national survey on the incidence of early onset 
Alzheimer's disease and further data on early onset disease is required (Treves et al,
1986).
Incidence studies have consistently concluded that increased age is a definite 
risk factor in Alzheimer's disease. Before the full interaction between age and this 
illness can be understood more information is needed at the extremes of the disease 
distribution. On current evidence it is likely that the incidence of Alzheimer's 
disease rises inexonerably with age and that there is a disease continuum between 
early and late onset disease.
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Table C. Selected incidence rates of undifferentiated dem entia  and 
Alzheimer's  disease.
STU D Y A G E  G R O U P  
(Years)
D IS E A S E IN C ID E N C E  
/ 100 000  pop
Schoenberg  1987 > 2 9 D ementia 187.5
M olsa 1982 >40 D ementia 58
>65 447
Nilsson 1984 70-75 D ementia (men) 17.7
75-79 32.3
Schoenberg  1987 >29 Alzheimer's disease 123.3
T reves 1986 <60 Alzheimer's disease 2.4
(b) Prevalence o f  A lzhe im er 's  disease.
Point prevalence is the num ber o f cases o f  disease in a population at one 
point in time, taken as a proportion o f the total population at the same point in time. 
Prevalence is frequently used to plan the allocation o f  health service resources and is 
a good indicator of the total disease burden in the com m unity  (Morris, 1964). 
Prevalence studies are, therefore, of obvious importance in A lzheim er's  disease.
Reported prevalence ratios vary considerably and any generalizations about 
the prevalence o f dem entia  are, like incidence studies, hazardous (Henderson and
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Kay, 1984). Consistent findings remain important and evidence of any change in 
prevalence of disease would be of interest.
The prevalence Alzheimer's disease and undifferentiated dementia increases 
with age (Table D). Meta-analysis of 22 pooled prevalence studies indicate that the 
prevalence of undifferentiated dementia doubles approximately every five years 
while that of Alzheimer's disease doubles every four and a half years, though actual 
prevalence rates varied considerably (Jorm et al, 1987).
Prevalence rates per 100 000 of population at risk have been calculated for 
presenile Alzheimer's disease, but small denominators make interpretation of these 
difficult. Rates range from 31.8 (C.I. 0-67.9) based on three people with the illness 
(Kokmen et al, 1989) to 34.7 (0-116.5) based, again, on three people (Schoenberg et 
al, 1985).
Disease prevalence is approximately equal to the product of disease 
incidence and mean duration of survival. Any variation in the prevalence of 
Alzheimer's disease would, therefore, indirectly signify a change in the natural 
history of the illness. Temporal variation in the prevalence of Alzheimer's disease 
has been studied by repeating studies in populations using identical methods to 
those used previously to allow direct comparisons. No significant change in the 
prevalence of Alzheimer's disease was demonstrated between rates in Rochester, 
USA in 1975 and 1980 (Beard et al, 1991) and between 1947 and 1972 in Lundby, 
Sweden (Rorsmanet al, 1986). This suggests there has been no major change in the 
incidence or mortality associated with the illness over time in these two locations.
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Table D. Selected prevalence rates for Alzheim er's  disease and 
undifferentiated dementia.
STUDY A G E  G R O U P D IS E A S E PR E V A L E N C E
(Years) ( %  pop at ri s k )
Z hang, 1990 >55 1.5
>60 Alzheimer's  disease 2.0
>65 2.9
Pfeffer et al, 1987 >65 Alzheimer's disease 15.3
>80 35.8
Rocca et al. 1990 >59 Alzheimer's disease 2.6
Evans et al, 1989 65-74 3.0
75-84 Alzheimer's disease 18.7
8 5 + 47.2
Erkinjuntti et al. >54 9.1
1986 55-64 Dementia 0.8
8 5 + 41 .4
Rocca et al, 1990 >59 Dementia 6.2
Z h a n g , 1990 >55 2.6
>60 Dementia 3 .5
>65 4.6
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(c) Survival in Alzheimer's disease
Epidemiological data on duration of survival in Alzheimer's disease is 
needed for a variety of reasons. A basic understanding of the prognosis of the 
disease is needed by all those caring for sufferers and relatives (councilling 
implications). Any change in duration of survival will significantly alter the 
prevalence of the illness (health care planning implications). A frequently used 
outcome measure in therapeutic trials is length of survival. A baseline measurement 
is required to assess efficacy of treatment (therapeutic implications).
Studies that attempt to define duration of survival in Alzheimer's disease 
have additional methodological difficulties. Alzheimer's disease is an insidious 
disorder and time of symptom onset may be subject to considerable information 
bias. Time of presentation to hospital care is usually more definitively obtained but 
excludes a large proportion of the natural history of the illness and is dependent on 
local health care provision and practice (McGonigal et al, 1992). In addition, it is 
likely that Alzheimer's disease has a prolonged asymptomatic "latent" period which 
may vary considerably between individuals and be dependent on a variety of ill - 
defined factors, for examples, stereotyped attitudes towards failing memory and 
individual acceptance of degrees of memory failure.
Most studies that have assessed survival time in Alzheimer's disease have 
been concerned with late onset disease (Go et al, 1978, Walsh et al, 1990). The 
illness does shorten life expectancy.(Go et al, 1978, Kay, 1962) but the effect of an 
early onset of disease on duration of survival is uncertain. Studies of survival 
duration in presenile Alzheimer’s disease are rare and have produced conflicting 
results: a significantly shorter duration of survival has been reported for early onset 
Alzheimer's disease in some studies (Barclay et al, 1985, Heyman et al, 1987), while 
others have found no such association (McGonigal et al, 1992, Hier et al, 1989).
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Estimates of mean duration of survival have been variously obtained for 
Alzheimer's disease: 7.1 years (Sjorgen et al, 1952) in a group of early onset 
disease, 5.7 years (Molsa et al, 1986) and 9.7 years (Hier et al, 1989) in groups of 
late onset disease. I have reported mean survival in presenile Alzheimer's disease to 
be 7.4 years, with sufferers taking an average of 3.2 years to present to hospital care 
(McGonigal et al, 1992).
The suggestion that survival duration in Alzheimer’s disease has improved 
in recent times remains unproven due to methodological limitations (Blessed and 
Wilson, 1982, Christie, 1982). These studies used hospital based populations from 
a variety of institutions and their conclusions may reflect changes in admission 
policy over time rather than improved survival. Another study has found no change 
in survival in patients with Alzheimer’s disease admitted to a single Toronto hospital 
over a ten year period (Thompson and Eastwood, 1981). The fact that prevalence 
has not altered significantly indicates that long-term survival has not altered in 
Alzheimer’s disease.
(d) Gender and Alzheimer’s disease.
Female gender is a recognised independent risk factor for Alzheimer's 
disease (Whalley, 1991). Incidence and prevalence studies have consistently found 
significantly higher rates in women compared to men (Zhang et al, 1990, Akesson et 
al, 1969, Molsa et al, 1982, Hagnell et al, 1983). Indeed, more than 13 population 
surveys and the meta-analysis by Jorm have supported the association (Jorm et al, 
1987). Whether the incidence of early onset A lzheimer’s disease is higher in 
females remains debatable. Several studies have reported similar incidence rates in 
males and females in this age group, but small numbers make interpretation of these 
results difficult (Treves et al, 1986, Molsa et al, 1982, Sulkava et al, 1983). If 
incidence rates of Alzheimer’s disease in males and females are differentially
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influenced by age of disease onset, then this would be of considerable aetiological 
importance.
Alternative explanations for the relationship between gender and 
Alzheimer’s disease are possible. It may reflect differences in the pattern of health 
care provision between the sexes (Pfeffer et al, 1987). Also, diagnostic bias may 
play a part. Rocca found that women had a higher prevalence of clinical 
Alzheimer's disease but that men had a higher prevalence of clinical multi-infarct 
dementia (Rocca et al, 1990). However a high proportion of people with multi­
infarct dementia clinically have neuropathological evidence of Alzheimer's disease 
(Buhl and Bojsen-Moller, 1988). Thus clinical limitations in the diagnosis of true 
disease could support erroneous relationships.
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G EN ETIC S O F A L Z H E IM E R ’S D ISEASE
The role of genetic factors in the aetiology of Alzheimer’s disease continues 
to be extensively researched and is relevant to clinical practice. The past decade has 
seen important advances in understanding the molecular genetics of familial 
Alzheimer's disease and related disorders. This chapter summarises these and their 
clinical relevance is discussed.
(a) Twin studies.
Twin studies have provided an informative starting point in the assessment 
of genetic risk in Alzheimer's disease. Estimation of concordance between 
monozygotic (with identical DNA genotype) and dizygotic (with different DNA 
genotype) pairs allows the likely importance of genetic factors to be quantified. 
Concordance for Alzheimer's disease between monozygotic pairs is approximately 
43% but in dizygotic pairs it is 8% (Kallman et al, 1951). The age at onset of 
Alzheimer's disease can, however, vary within monozygotic and dizygotic twin pairs 
and discordant pairs may subsequently become concordant (Cook et al, 1981). An 
approximate concordance of 40% is suggested for both monozygotic and dizygotic 
twins (Nee et al, 1987).
Discordance and variability of age at onset of Alzheimer's disease in 
monozygotic twin pairs is unlikely to result from genetic heterogeneity (though 
recently the effects of maternal mitochondrial genes has been hypothesized) and 
provides evidence against a simple genetic cause of the disorder. Twin studies 
provide support for genetic factors in Alzheimer's disease yet indicate that factors 
other than genetic may modify genetic expression in some instances of the disorder.
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(b) Pedigree studies.
Many examples of families in which Alzheimer's disease seems to follow 
autosomal dominant inheritance are reported (Nee et al, 1983, Landy et al, 1970). 
Although there is one single report of a family in whom only women developed the 
disorder, this is so unusual as to effectively discount the likelihood of X-linked 
transmission (Posteraro et al, 1988). Most studies suggest that familial Alzheimer's 
disease is transmitted as an autosomal dominant trait in a proportion of early onset 
families. In others, however, most pedigrees provide too few data to be confident 
about the mode of transmission, a feature that is largely related to the late onset at 
age of disorder and the fact that many informative first-degree relatives have yet to 
complete most of the period of risk for Alzheimer's disease. In addition, few 
pedigrees have more than one autopsy-validated diagnosis of Alzheimer's disease.
In summary, the majority of sufferers of Alzheimer's disease have a late onset 
disorder and it is by no means clear that the unusual early onset pedigrees with 
autosomal dominant inheritance can provide data that are relevant to the majority of 
patients with Alzheimer's disease.
(c) Proband studies.
Population proband studies have been used to clarify inheritance of 
Alzheimer's disease. Sjorgen (Sjorgen et al, 1952) has suggested that multifactorial 
inheritance provided the most likely explanation of the patterns of inheritance he 
observed in his sample of Alzheimer's early onset cases in Sweden. His study did 
not include late onset patients. Larson (Larson et al, 1963) has suggested autosomal 
dominance is the likeliest explanation of his observations, again in Sweden, and his 
conclusions appear robust almost 30 years later (Mohs et al, 1987). Other studies 
suggest an estimated cumulative lifetime risk in first degree relatives of probands 
with Alzheimer's disease of approximately 50%, in keeping with a presumed
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autosomal dominant mode of inheritance (Mohs et al,1987, Martin et al, 1988, Farrer 
et al, 1990). Further studies have shown that cumulative lifetime risk of Alzheimer's 
disease in the relatives of early onset probands is approximately 50% but that the 
relatives of late onset probands appear to be at much lower risk (Heston et al, 1981, 
van Duijn et al, 1991). In addition, the relative risk in Alzheimer's disease is known 
to increase substantially with increases in the number of first degree relatives 
affected by dementia.
These observations have prompted the suggestion that there may be several 
genetically distinct sub-types of Alzheimer's disease and that these include a non­
inherited sub-type (Fitch et al,1988, Chandra and Schoenberg, 1989). The 
hypothesis of genetic heterogeneity is supported by evidence of intra-familial 
correlations in age at onset. The relatives of early onset probands who develop 
Alzheimer's disease have a significantly lower age of onset than affected relatives of 
late onset probands (Breitner et al, 1988, Powel and Folstein, 1984).
Proband studies do not prove conclusively that Alzheimer's disease is 
transmitted as a autosomal dominant trait but do support the twin and pedigree 
studies that suggest a strong genetic component in the risk of development of the 
disorder. Alzheimer's disease is highly prevalent in old people and some instances 
of dementia in the relatives of probands with the disorder may be coincidental, an 
inference that would be supported by the small sample size of many studies. Shared 
environmental factors may also be important.
(d) Genetic linkage studies.
Amyloid protein precipitates in the brains of patients with Alzheimer's 
disease especially in senile plaques and vessels (Glenne and Wong, 1984). The 
protein (amyloid b protein) is quite specific and is found in Down's syndrome and 
Alzheimer's disease (Glenne and Wong, 1984, Musters et al, 1985).
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Characterization of the structure of amyloid b protein has been a major step in 
genetic linkage studies as it has allowed complementary DNA (cDNA) clones of 
amyloid b protein to be analysed (Goldgarber et al, 1987). Sequence analysis 
revealed amyloid b protein to be part of a large precursor protein (amyloid precursor 
protein, APP) that is highly conserved in vertebrate evolution and may function at 
the cell membrane (Kang et al, 1987). Amyloid b protein is found in senile plaques, 
the walls of cerebral vessels and within surviving neurones in Alzheimer's disease.
It is also found in the brains of many old people not affected by dementia.
Molecular genetic studies have sustained two separate approaches to the 
genetics of Alzheimer's disease. Firstly, the APP gene was mapped to chromosome 
21, as predicted by the Down's syndrome model of Alzheimer's disease (Goldgarber 
et al, 1987, Goate et al, 1989). Secondly, linkage studies identified a locus on 
chromosome 21 that segregated with Alzheimer's disease in affected families at a 
site close to, but not identical with, the APP gene (St George Hyslop et al, 1987, 
Hardy et al, 1989). Although an early study claimed detection of a gene dosage 
effect of excess APP expression in Down's syndrome and Alzheimer's disease, it 
soon became clear that this was unlikely and, more importantly, that Alzheimer's 
disease, as revealed by molecular genetic studies was a genetically heterogeneous 
group of disorders. Patients with late onset disease and many early onset cases did 
not show linkage to a chromosome 21 locus (Tanzi et al, 1987, Podlisny et al, 1987). 
The extent and precise quantification of genetic heterogeneity in Alzheimer's disease 
could be potentially resolved by molecular genetic techniques. So far, an uncertain 
proportion of early onset Alzheimer patients have been shown to carry a defect in 
the APP gene, although its precise nature varies between families. Three different 
point mutations on the APP gene have been identified in eight families (Goate et al, 
1991, Murrell et al, 1991, Chartier-Harlin et al, 1991). Although it is premature to 
argue for a molecular biological classification of the dementias, such an approach
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might become mandatory if the technique leads to the ready identification of 
mutations elsewhere in the APP gene and their frequencies in affected and non­
affected populations.
(e) Platelet membrane fluidity.
"Membrane fluidity" decreases with age from 40 to 90 years. Platelet 
membrane fluidity is increased in Alzheimer's disease and a genetic basis for this 
abnormality has been proposed (Zubenko et al, 1987(b)). When the 90th centile for 
elderly patients is used to classify Alzheimer's disease patients (Zubenko et al 
1987(a), Cohen and Zubenko, 1985) two subgroups can be identified. In one there 
is increased platelet membrane fluidity with an earlier onset and more rapid course 
of dementia. In this group there is often a family history of dementia. These 
findings may be relevant to the abnormal ageing hypothesis of Alzheimer's disease 
and to premature senescence..
Summary.
There is a substantial genetic contribution to the risk to develop Alzheimer's 
disease. The existence of a first degree relative with Alzheimer's disease increases 
the risk by about two-fold and in some instances of early onset Alzheimer's disease 
the gene responsible is probably on chromosome 21 and in a minority of cases, the 
abnormality can be precisely located to the APP gene. However, differences 
between monozygotic twin pairs in Alzheimer's disease suggest that non-genetic 
factors may also be important. Most genetic hypotheses make reference to possible 
mutations that lead to the formation of brain proteins that are difficult to degrade and 
to exclude from the nerve cells. Several metabolic pathways have been carefully 
examined in Alzheimer's disease and a great deal is now known about the molecular 
biology of brain amyloid. Unfortunately, little is known about the molecular
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biology of the neurofibrillary tangle only about 10% of which has been structurally 
characterized.
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NEURONAL AGEING. DEMENTIA AND ALZHEIMER’S DISEASE
“In fact to draw a distinction between disease and normal ageing is to attempt to 
separate the undefined from the indefinable”
The previous chapter on genetics highlights one major risk factor for the 
developement of Alzheimer’s disease, this chapter explores another - Age. To 
appreciate the interrelationship between physiological ageing processes and 
Alzheimer’s disease it is necessary to examine the boundaries between ‘normal’ 
neuronal ageing, dementia and Alzheimer’s disease.
Normal Neuronal Ageing
This starts in utero. From the earliest period of development large number 
of cells die as a result of 'programmed cell death' (Schwartz LM, 1991). This 
process is vital in sculpting body form, removing vestigial tissues, maturation and 
ultimately, senescence. A cells 'decision' to die is a differentialve event under 
specific genetic control which has, presumably, been open to evolutionary influences 
(Charlesworth, 1980). In man, a species with extensive genetic heterogeneity, 
thousands of genes may be involved in modifying and controlling this process and, 
therefore, senescence phenotype.
Two common hypotheses of ageing are the 'wear and tear' ( neuronal fallout 
model ) and the 'use it or lose it' ( plasticity m odel) theories. The former commonly 
uses the analogy of a large boulder being worn down to rubble by the tides of time 
(Hanley, 1974). As cells are stimulated and used, they are more likely to die. This 
progressive process relentlessly reduces the functional reserve of the brain until 
cognitive changes appear. The rate of decline is individually determined by
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genotype and environmental influences. Modification of this process would either 
require genetic manipulation of'programmed cell death' or, alternatively, an 
understanding of the interaction between environment and genotype. Both these 
solutions are not obtainable at present.
The 'use it or lose it' theory argues that the physiological activation of cells 
may maintain them (Curzio et al, 1982). Some neurones can grow and alter function 
in response to unexpected challenges; neurones that do not die may take over the 
function of those that do. This could explain the recovery of various neuronal 
systems during ageing after the restoration of missing stimuli. Environmental 
therapies could, in theory, produce successful ageing and be applicable now. 
However, neuronal ageing is a complex, heterogeneous physiological process not 
easily fitted to any model.
The differentiation of disease from normal ageing is a dilemma which 
confronts clinicians daily. Nowhere is this more true than in the care of patients 
with dementia. Memory loss is considered a cardinal feature of senescence, and yet 
is a hallmark of dementing illnesses (Finch and Landfield, 1985, Martin, 1978, 
Murphy, 1978). Not surprisingly, the boundaries between pathological state and 
physiological cognitive decline are not well defined. Indeed, no categorical 
boundary exists, but the change from ‘normal cognitive function’ to dementia is a 
threshold phenomenon controlled by a variety of divergent processes (Meier-Rage 
et al, 1991). Clinicians, through greater awareness about the importance of accurate 
diagnosis of dementing illnesses, have a crucial role to play in defining this 
boundary.
Cognitive Ageing and Dementia.
Physiological cognitive ageing is an ill-defined entity which is confounded 
by functional, sociological and pathological considerations (O ’Connor et al, 1991).
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Old people expect their memory to faulter and are more likely to complain about 
memory loss, which is not necessarily congruent with actual memory functioning 
(Jarvik and Falek, 1963, Kahn et al, 1975). These negative sterotypes of age have 
been questioned and well-designed longitudinal studies have associated memory 
deterioration with increased mortality (Schaie KW, 1974). In addition, level of 
education and co-existent physical and psychiatric illness all influence what should 
be considered 'physiological' cognitive functioning for an individual (O ’Connor et 
al, 1991). Lack of substantial population-based normative data make this a difficult 
clinical decision (Gangali et al, 1991).
The diagnosis of dementia is warranted only if there is demonstrable 
evidence of memory impairment, that along with other features of dementia, is of 
sufficient severity to interfere with social or occupational functioning (ICD - 10, 
DSM-III-R). Dementia is not synonymous with ageing, but must take into account 
the cognitive performance of an individual over time. It has a threshold set between 
health and sickness dependent on social function. Sociodemographic factors (e.g, 
age, sex, social class, education, race, ete) are important determinants of this 
threshold in an individual. This is not dissimilar to many medical conditions where 
an individual's ability to adapt to their environment is the principal determinant of 
disease state.
The putative differentiation between ageing and dementia based on clinical 
assessment of cognitive function is problematical. The threshold hypothesis 
necessarily incorporates a social dimension which favours a continuum between age 
and dementia rather than discrete categorisation. Since cognitive impairment implies 
a decline from a healthy level of cognition for an individual, a reference range for 
normal cognitive function is needed which accounts for confounding 
sociodemographic factors. A baseline in which the influences age and education 
have been evaluated can be provided by the National Adult Reading Test (NART),
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which estimates pre-morbid Intelligence Quotient (IQ) and is stable in dementia.
Old people with the greatest discrepancy between observed cognitive function and 
that expected when age and NART-predicted IQ are taken into account will lie 
towards the disease end of the age-dementia continuum, and may merit further 
investigation (Starr et al, 1992). This enables quantification of what doctors have 
known for a long time that, at the same level of current mental ability, they should be 
more concerned about a patient who was once a professor than one who had been a 
labourer.
Dementia is not a discrete diagnosis but a sympom complex with over 100 
different causes (McGonigal et al, 1992). In addition to differenting symptoms of 
dementia from those of normal cognitive ageing, another difficulty arises in the 
diagnosis of the specific pathology. In many instances this can be straightforward 
(for example, dementia pugilistica and dialysis dementia), but the differentiation 
between Alzheimer's disease, the commonest cause of dementia, and normal 
cognitive ageing is much more difficult.
Alzheimer's disease and 'normal' cognitive ageing.
Increased age is an unequivocal risk factor in Alzheimer’s disease and it 
may affect upwards of 50% of people in their ninth decade (Jorm et al, 1987). In 
one sense, then, it is ‘norm affor the very old to have Alzheimer’s disease, which 
could be viewed as a model of accelerated ageing. This simplistic model of 
Alzheimer’s disease is unacceptable without further clarification as indicated by an 
example from tropical medicine. Onchocerciasis is a filarial infection which is 
responsible for up to 35% of middle aged and elderly people being blind in regions 
of Africa. There is a considerable delay between the initial infection and blindness. 
Visual impairment is also a principal feature of old age, but no-one would consider 
onchocerciasis a model of accelerated ageing because there is a definitive
41 Alzheimer’s disease in Scotland
aetiological agent, associated eye pathology is distinct from that seen in the elderly, 
and other body organs are unaffected.
Just as the clinical paradigm is a continuum  between disease and age, so too 
are the neuropathological findings (Table E). T here  is no pathognom onic feature of 
A lzheim er's  disease that cannot be found in the brains o f  'normal' non-dem ented  old 
people. The difference between physiological cognitive ageing and Alzheimer's  
disease is based on sym ptom s o f  dem entia  and the degree o f organic change, not 
uncom m only  decided with the benefit o f  hindsight!
fa b le  E. Features o f  “ no rm al” age ing  and A lz h e im e r ’s disease.
FEA TU R E AGEING A L Z H E IM E R 'S
C L IN IC A L  
Cognitive Impairment ? /  + + + +
N E U R O H IS T O L O G IC A L  
Neuritic Plaques + / ++ + + +
Neurofibrillary Tangles + / - + + +
Cortical Neuronal Loss + + + +
N E U R O C H E M IC A L  
Cortical Choline 
Acetyltransferase decrease + + + +
Somatostatin reduction + + +
R A D IO L O G IC A L  
Cerebral atrophy + / ++ + +  / ++ +
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Unsurprisingly, biological and clinical markers for Alzheimer's disease have 
remained elusive, since they would need to exhibit a strong association to be 
detectable. One promising area is that of neuroimaging, where functional data 
collected by single photon emision or positron emission tomography can be 
combined with the structural data from the more standard techniques of 
computerised tomography and magnetic resonance imaging. Yet even if their 
promise is fulfilled, such investigations are unlikely to be available to most elderly 
people with unexplained memory loss.
Interaction between age and Alzheimer’s disease
A clear distinction between cognitive impairment associated with ‘normal’ 
ageing and that secondary to Alzheimer’s disease cannot be easily made on clinical 
or pathological grounds. The relationship between disease (Alzheimer’s disease) 
and non-disease (normal ageing) can be considered in five interactions proposed by 
Ottman, synthesised in the figure A (Ottman, 1990).
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Figure A. Interactions between Ageing and A lzh e im er 's  disease.
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(1) G enotype does not cause a disease directly but acts by increasing the level o f  
expression o f  a risk factor. If the risk factor for A lzh e im er 's  disease is age. 
individual genotype m ay m odify  its expression.
(2) Risk factor has a direct effect on the disease (and may cause it directly ). but 
genotype influence this effect (though genotype has no effect on its own). 
A lzhe im er 's  disease could be an inevitable consequence of ageing; its effects being 
modified by individual genotype so that some patients develope the disease early, 
while in others the potential expression o f the disease is limited by hum an life-span.
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(3) Genotype has a direct effect on the disease (and may cause it directly) but 
risk factors influence this effect (though the risk factor has no effect on its own). 
Alzheimer’s disease may be caused entirely by genetic factors, their expression 
being influenced by age and other environmental influences.
(4) Both genotype and risk factor can influence the disease by themselves, but 
the risk increases when both are present. The combination of genetic susceptibility 
and age may interact either additively or multiplicatoiy to increase the risk of 
Alzheimer’s disease.
(5) Genotype and risk factor can influence disease risk independently. Genetic 
linkage linkage studies have proven that a minority of patients with Alzheimer’s 
disease have a direct genetic cause, whether age can cause Alzheimer’s disease 
independently remains open to debate (the ageing hypothesis of Alzheimer’s 
disease).
The aetiological case for a dichotomy between Alzheimer’s disease and 
ageing depends on genetic studies. Down’s syndrome has proved a useful model. 
Trisomy of chromosome 21 is associated with an Alzheimer’s type dementia which 
is neurohistologically indistinguishable from senile Alzheimer’s disease (Musters et 
al, 1985). Other features of premature ageing found in Down’s syndrome are a 
greater incidence of age-related neoplasia, premature hair greying and loss, amyloid 
and lipofuscin pigment deposition, diabetes mellitus, hypogonadism, degenerative 
vascular disease and cataracts. This model favours Ottman’s paradigm (1) with 
increased free radical damage and impaired DNA repair as the probable molecular 
biological mechanisms responsible (Boerrigier ME et al, 1991). On the other hand,
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mutations detected in pedigree studies suggest underlying abnormalities of amyloid 
processing consistent with paradigm (5)(Murrell et al, 1991). The other interactions 
fall between these two extremes.
Summary
The overlap between normal cognitive ageing and Alzheimer’s disease is 
great and presents a diagnostic dilemma to physicians. Reaching a diagnosis has 
practical importance in councilling patients and relatives and, on a wider stage, 
planning health service requirements. Although cognitive impairment is present in 
both ‘normal’ ageing and Alzheimer’s disease, the rate of progression is typically 
greater in the disease state. Diagnosis is further hampered by negative stereotypes 
of memory loss and remains predominantly one of clinical judgement. The danger 
of diagnosis in such a difficult situation is that it may deceive doctors into the belief 
that they know more than they do. Labelling a patient as demented without further 
quantification as to specific disease and to the degree of cognitive impairment is 
relatively uninformative about prognosis
The boundaries between normal cognitive decline, dementia and Alzheimer’s 
disease remain blurred. The interaction between age and Alzheimer’s disease is 
complex and not understood. Clinicians have a vital role to play in defining these 
boundaries. Accurate diagnosis of the specific causes of dementia, based on sound 
clinical practice and re-evaluation of patients over time, will improve the quality of 
data available on such patients. The epidemiology of the causes of dementia and of 
ageing could then be described, aetiological associations discovered, public health 
programmes instituited and councelling services improved.
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ALUMINIUM AND ALZHEIMER'S DISEASE
Aluminium is the third commonest element on the earth's surface and the 
commonest metallic substance. Exposure to environmental aluminium may be 
associated with the development of Alzheimer's disease (Martyn et al, 1989, Michel 
et al, 1990). In this review the basic chemistry, human physiology and evidence that 
links aluminium to Alzheimer's disease is examined.
Environmental Aluminium Exposure
Aluminium sulphate, the common naturally occuring form of aluminium, has 
a simple ionic structure at acidic pH, but at neutral pH it becomes highly complexed 
and water insoluble. A European Community overview found the concentration of 
naturally occuring aluminium in groundwater at neutral pH to be very low 
(<0.05mg/l), but accepted that it may be higher in areas subject to acid rain 
(Simpson et al, 1988). Most aluminium is removed from the public water supply in 
the purification process, however geographical variation in the concentration of 
aluminium in the water supply exists (Martyn et al, 1989). Man is also exposed to 
aluminium in the household. It is commonly found in cookware, in food additives 
and in a number of non-prescription drugs (Lione 1985, Tennakone and 
Wickramanayake, 1987).
Human Physiology
Most absorption of aluminium occurs in the gut (Alfrey, 1980) but small 
amounts are absorbed along olfactory pathways (Rifat et al, 1991, Perl and Good, 
1987). An estimated average daily intake of aluminium is 20mg orally (range 1- 
100) and3-15ug via inhalation. The plasma level of aluminium is between 1.5-
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15ug/l and total body aluminium is estimated at 30-45mg/l (Jones and Bennet, 1985, 
Perl and Good, 1987). This contrasts with its natural abundance and reflects the 
insolubility of naturally occuring aluminium, the gastro-intestinal barrier to 
absorption and the efficiency of renal excretion (Ganrot, 1986).
Aluminium follows the iron transport pathway in the extracellular 
environment and is bound to transferrin and lactoferrin (Trapp, 1983). This 
aluminium-transferrin complex is stable enough to suppress any interaction of 
aluminium with all other ligands in plasma (Martin, 1986). Much is unknown about 
the intracellular actions of aluminium. It may coexist with iron in the cytosolic labile 
iron pool (May and Williams, 1980) and affect a number of molecular biological 
responses. For example, aluminium may inhibit the incorporation of inositol into 
phospholipids at the cellular level (Johnson and Jope, 1986).
Neurotoxicity of aluminium.
In 1962 a single case report linked pulmonary fibrosis and encephalopathy 
to the inhalation of aluminium dust (McLaughlin et al, 1962). However, no further 
case reports linking aluminium dust inhalation and encephalopathy have been 
described. Animal studies provided some evidence for the neurotoxic effects of 
aluminium but definitive proof occured with the discovery that the encephalopathy 
experienced by renal patients on dialysis was caused by a high concentration of 
aluminium in the dialysate (Wills and Savoy, 1983, McClure and Smith, 1984, 
O'Hara and Mamaghan, 1982). Furthermore, this encephalopathy responded to 
aluminium chelation therapy with desferrioxamine and so was, in part, treatable 
(Sprague et al, 1986). The encephalopathy is, however, clinically and 
neuropathologically distinct from Alzheimer's disease (Walton, 1991).
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Aluminium and Alzheimer’s disease
(a) Animal evidence - a historical perspective
Animal studies provided the first indication that there could be an association 
between aluminium and Alzheimer's disease. In 1965 the injection of aluminium 
chloride into the central nervous system of rabbits lead to the development of 
neurofibrillary tangles, a neuropathological feature of Alzheimer's disease (Klazo et 
al, 1965, Terry and Pena, 1965). It was hoped that this discovery could result in a 
reliable animal model to facilitate research into Alzheimer's disease, however the 
tangles were histologically distinct to those found in human disease (Terry and 
Pena, 1965, Troncoso et al,1986). In addition, there is wide interspecies 
susceptibility to the neurotoxic effects of aluminium which makes the validity of any 
animal model doubtful (Wisniewski et al, 1980).
Animal studies have described some in vivo actions of aluminium that may 
be important in man and in Alzheimer's disease. For example, aluminium increases 
the permeability of the blood-brain barrier (Banks and Kastin, 1983) and alters 
cyclic AMP and cyclic GMP levels in the rat (Johnston and Jope, 1987). Despite 
the problems with the validity of animal studies in relation to man they could 
facilitate a greater understanding of the molecular biological actions of aluminium in 
normal and disease states.
(b) Human evidence
Aluminium is present in the central nervous system of man at a 
concentration of approximately two parts per million (Crapper McLachlan, 1986). 
Several studies have suggested that the concentration of aluminium in the brains of 
patients with Alzheimer's disease is increased compared to controls (Crapper et al, 
1973 and 1980, Edwardson and Candy, 1989). Other studies have not found this 
association and the evidence remains inconclusive (Markesburg et al, 1981, Trapp et
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al, 1978). Aluminosilicates are present in the senile plaque core, a neuropathological 
feature of Alzheimer's disease (Candy et al, 1986) and in neurofibrillary tangle 
bearing neurones (Perl and Brody, 1980). However, whether this accumulation is 
caused or effected by Alzheimer's disease is unknown.
Epidemiology has provided some evidence that aluminium may be 
associated with Alzheimer's disease. On a general level there is evidence that the 
encephalopathy experienced by residents of Guam is caused by an environmental 
toxin and is not due to mutational events in the genetic pool (Garruto et al, 1985, 
Reed and Brody, 1975). The water on Guam contains a high concentration of 
aluminium (and a low concentration of calcium and magnesium) and there is 
evidence of aluminium accumulation in the neurones of patients with this 
encephalopathy (Perl et al, 1982). This illness provides an epidemiological model of 
a chronic dementing disease which may be caused by environmental toxins of which 
aluminium is clearly implicated.
In Alzheimer's disease there is inconclusive evidence that a raised 
concentration of aluminium in the public water supply may be associated with 
Alzheimer's disease (Martyn et al, 1988, Flatten, 1986, Michel et al, 1990, Neri and 
Hewitt, 1991). Primarily problems with study design, population migration and 
disease diagnosis have resulted in caution in the interpretation of these studies but 
they all support a possible association between environmental aluminium exposure 
and the development of Alzheimer's disease. Definite causation or even association 
has not been established and one study has failed to find any association (Wettstein 
et al, 1991).
A therapeutic study has assessed the response of patients with Alzheimer's 
disease to treatment with desferioxamine (CrapperMcLachlan et al, 1991). The 
study was a two year single blind study and there was some evidence that treatment 
slowed the rate of decline in daily living skills in patients with Alzheimer's disease.
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Desferioxamine chelates aluminium along with a large number of other metals and 
reduces iron-mediated free radical formation. Further evaluation is required before 
its mode of action in Alzheimer's disease is quantified and understood.
Summary
Aluminium is a common naturally occuring element and exposure to it in the 
environment is almost inevitable. Ironically this means that epidemiological proof of 
a direct causal association between aluminium and Alzheimer's disease will be 
difficult to prove. Aluminium is mainly absorbed via the gut and is present in the 
central nervous system in small concentrations in normal people. The 
encephalopathy associated with renal dialysis showed that aluminium is neurotoxic 
to humans, however its role in the aetiology of Alzheimer's disease remains 
speculative and controversial. The distinction between aetiology and pathogenesis 
remains unproven though animal, epidemiological, neuropathological and therapeutic 
studies suggest an association may exist.
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OTHER RISK FACTORS AND ALZHEIMER'S DISEASE
Previous chapters have discussed estabished risk factors for A lzheim er’s 
disease and one factor which remains controversial, the role of aluminium in the 
disease. A variety of other risk factors have been implicated in the aetiology of 
Alzheimer's disease. The suggested association between head trauma and the 
disease has been most extensively investigated and is considered in some detail. 
Other associations are listed but none have been definitively proven and remain 
speculative.
Head Trauma and Alzheimer’s disease.
The development of dementia after recurrent head trauma, for example in 
boxing, is well established - dementia pugilistica or 'the punch-drunk syndrome' 
(Corsellis, 1978, Wisniewski et al, 1976). Neurofibrillary tangles, indistinguishable 
from those that are hallmarks of Alzheimer's disease, occur in abundance in the 
cortex of such patients (Corsellis, 1978, Roberts, 1988). More recently, neuronal 
plaques have also been described (Roberts et al, 1990). This has led to the 
hypothesis that dementia pugilistica and Alzheimer's disease may share a common 
pathogenesis.
Several case-control studies have found a significantly increased frequency 
of head trauma in patients with Alzheimer's disease compared to age-sex matched 
controls (Heyman et al, 1984, Mortimer et al, 1985). Others have found an excess 
of head trauma in patients which did not reach statistical significance (Shalat et al, 
1986, Amaducci et al, 1986) or have found no association (Chandra et al, 1987, 
Bharucha et al, 1983). A small study has even demonstrated a reverse association
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with a history of head trauma more common in controls compared to patients with 
Alzheimer's disease (Soininen and Heinonen, 1982).
All case-control studies performed to test the hypothesis that an association 
exists between a history of head trauma and the development of Alzheimer's disease 
have been too small to test the hypothesis adequately. Meta-analysis is a method 
that can increase statistical power. Seven pair-matched case-control studies have 
been pooled and re-analysed (Mortimer et al, 1991). The findings support a 
significant association between head trauma with loss of consciousness and 
Alzheimer's disease with an increased odds ratio of 1.82. However, caution is 
required in the interpretation of these results because there a number of possible 
sources of bias.
Selection bias is always a major concern in case-control studies. Data 
collection in the case-control studies combined for the meta-analysis was not 
standardised; different criteria were used to define Alzheimer's disease, head 
traumatized and community controls. Although the meta-analysis pooled studies 
with community controls only, case-control studies that used controls sampled from 
hospital populations reported higher odds ratios (Mortimer et al, 1985, Amaducci et 
al, 1986). Information or recall bias is another source of error. Patients and / or 
informants are more likely to remember a head injury if they are suffering from a 
neurological disease. The meta-analysis was restricted to case-control studies in 
which severe head trauma with loss of consciousness was used to define injury in 
the belief that this would be less subject to recall bias. Finally, it is possible that 
confounding factors may result in systematic error. For example, there is a 
suggestion that head injury may hasten the onset of Alzheimer's disease (Gedye et 
al, 1989). People who would have developed dementia in old age or in whom their 
finite human-life span would have prevented expression of the disease may develop
53 Alzheimer’s disease in Scotland
symptoms earlier because of head trauma. This could result in a spurious 
association being found between the illness and head trauma.
In summary, there is increasing evidence that severe head trauma and 
Alzheimer's disease are associated, but the association remains unproven. There is a 
need for a large sample prospective epidemiological survey set up specifically to 
address the issue.
Some other suggested associations
A plethora of other conditions have been linked to Alzheimer's disease with 
inconclusive results (Table F). Studies have been to small to adequately test the 
reported associations and biases further limit their conclusions. For example, a 
history of heavy alcohol consumption excludes a diagnosis of clinical Alzheimer's 
disease in many studies because it is a cause of cognitive impairment in its own 
right. Alcohol consumption is positively associated with head trauma, which could 
further confound results. Furthermore, many studies were not designed to assess 
one specific risk factor and the effects of data 'dredging' may be significant. Again, 
well designed prospective studies are needed to test each proposed association.
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Table F. Selected conditions that have been linked to A lzhe im er’s disease.
P R O P O S E D
A S S O C IA T IO N
S IG N IF IC A N T
A S S O C IA T IO N
N O  S IG N IF IC A N T  
A S S O C IA T IO N
H ypothyro id ism Hey man et al. 1984 Lopez et al, 1989
Atopy N one A maducci et al, 1986
Alcohol N one G raves et al, 1991
Sm oking  (protective) Hofm an et al, 1990 Barclay et al, 1989
Sm oking  (increase risk) Shalat et al. 1987
55 Alzheimer’s disease in Scotland
Section 2: The epidemiolo2V of Alzheimer’s presenile dementia in Scotland
1974-88
AIMS, DESIGN AND HYPOTHESIS
Aims
The following questions will be answered:-
(a) Can current clinical criteria used to diagnose Alzheimer’s disease be 
improved and modified for specific use in epidemiological research?
(b) What is the incidence rate of presenile Alzheimer’s disease in Scotland?
(c) Is gender a risk factor in presenile Alzheimer’s disease?
(d) What is the natural history of presenile Alzheimer’s disease?
Design
The literature review provides an introduction to this thesis. Alzheimer’s 
disease is the commonest type of primary degenerative dementia and although 
presenile disease is much rarer it represents an important form of the illness. The 
study sample will be derived from retrospective scrutiny of hospital and public 
records identified from central and local data collection systems. The reference 
population is the Scottish population. This observational ‘historical’ design has a 
number of advantages: -
(1) A large number of people with presenile dementia can be ascertained 
within the financial constraints of the study.
(2) National Scottish data can be described.
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(3) Sufficient people with presenile Alzheimer’s disease who underwent 
neuropathological examination will be described and clinical diagnostic 
criteria used to define the illness can be critically evaluated.
Scotland is uniquely placed for this type of epidemiological research. There 
are well organised health services with, relative to the population size, reasonable 
neuropathological and neurological investigative facilities. The Information and 
Stastics Division (ISD) of the Scottish Home and Health Department maintains a 
computerised record of all admissions, discharges and deaths from all general and 
psychiatric hospitals. Within the constraints of normal ethical procedure, this 
information is readily available. In addition, a number of hospitals, neuropathology 
and neurology departments maintain independent local diagnostic registries of 
patients with presenile dementia.
The aims of this study can be achieved if a valid and reliable population of 
people with presenile Alzheimer’s disease can be described. The study sample will 
comprise patients who were admitted, discharged or had died in psychiatric hospitals 
within Scotland between 1974 and 1988 and who were identified through ISD. The 
validity of this sampling method will be tested by reference to other independent 
data sources.
Two major assumptions have been made in this sampling frame. Firstly, that 
the identity of all patients with presenile Alzheimer’s disease who have been 
admitted to psychiatric hospitals can be reliably obtained from ISD. This 
assumption will be tested in the pilot study. Secondly, that the majority of people 
with presenile Alzheimer’s disease are admitted to psychiatric institutions at some 
stage in their illness. This will be tested by reference to general hospital data, death 
certificate data obtained from the Registrar General of Scotland and selected 
neurology diagnostic registries.
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Important methodological concerns about the study design will be 
discussed: -
(i) Admission policies for patients with presenile Alzheimer’s disease may 
vary between psychiatric hospitals.
(ii) Hospital record quality may show temporal and geographical variation 
across Scotland.
(iii) The availability of psychiatric health care may be different between 
geographical regions in Scotland.
(iv) The effects of population migration between small geographical areas in 
Scotland may be significant and limit the usefulness of reporting local 
incidence rates of Alzheimer’s disease.
These considerations could have profound effects on completeness of 
patient ascertainment and be a source of systematic bias. Adequacy of case 
ascertainment will be discussed in detail in the discussion section of the thesis.
Hypothesis
The hypothesis that “Female gender is an independant risk factor for 
presenile Alzheimer’s disease” will be examined in detail.
Female gender has become an established risk factor for senile Alzheimer’s 
disease. However, the relationship between female gender and the risk of presenile 
disease is controversial. If the influence female gender has on the risk of 
Alzheimer’s disease is age dependent then this will be of aetiological importance. It 
would suggest that either presenile and senile Alzheimer’s disease are differentialve 
pathological processes or that changing female physiology with age alters disease 
risk.
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PILOT STUDY
Summary
The Information and Statistics Division (ISD) of the Scottish Home and 
Health Department maintains a computerised record of patients who have been 
admitted to, discharged from or have died in Scottish psychiatric hospitals. This 
chapter assesses the quality of these data in relation to patients with verified 
presenile dementia who have been discharged from the Royal Edinburgh Hospital 
between 1974 and 1988. The accuracy and completeness of ISD data is evaluated 
by comparison with data available from the hospital’s independent diagnostic 
register and information obtained after hospital record scrutiny.
17% of presenile patients were not identified and 23% of patients were 
wrongly classified on ISD data. More than 93% of patients with presenile 
Alzheimer's disease were identified, though often under a variety of other diagnostic 
codes. 1 % of hospital records contained insufficient information to validate the 
diagnosis of presenile dementia.
The feasibility of using ISD data to define an unbiased national sample of 
people who have suffered from presenile Alzheimer’s disease is discussed. Caution 
is needed in such an approach and other independent data sets would need to be 
explored to validate the population sample.
Background
The main body of work will rely on the identification of all patients with an 
onset of symptoms of Alzheimer’s disease under age 65 years who were admitted to 
a psychiatric hospital in Scotland between 1974 to 1988. In theory, clinical and
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demographic information is available for all patients admitted to psychiatric 
hospitals. A SMR-4 form is completed for each patient on admission , discharge or 
death from hospital and details sociodemographic information and diagnostic codes 
selected from the International Classification of Disease (ICD - 9, 1977). The data 
contained are checked for clerical errors at the hospitals and at the Information and 
Statistics Division (ISD) of the Scottish Home and Health Department before being 
stored on computer. However, the usefulness of the data is dependent upon its 
quality.
Dementia is a symptom complex and not a discrete diagnosis. A patient 
with dementia should receive two ICD diagnostic codes: a general code classifying 
dementia and a specific code to describe the presumed cause. Those who develop 
symptoms of dementia under the age 65 years are coded as presenile dementia, older 
patients as senile dementia. The accuracy of the diagnostic code documented on the 
SMR-4 form can be evaluated in patients with Alzheimer’s disease by reference to 
standard clinical criteria.
Aims and Objectives
The pilot study has the following aims:-
(1) To define the nature of the data request to ISD to identify patients with 
presenile Alzheimer’s disease who have been admitted to psychiatric hospitals in 
Scotland.
(2) To critically evaluate the accuracy and completeness of data available 
from ISD.
(3) To assess the feasibility of applying diagnostic criteria for A lzheimer’s 
disease to psychiatric hospital records.
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Method
The Royal Edinburgh Hospital is the largest psychiatric hospital in Scotland 
and medical record staff maintain an independent register of patients who have been 
admitted to, discharged from or have died in the hospital. The register was used to 
provide a list of patients aged less than 73 years who had in-patient treatment 
between 1974 and 1988 and who were given ICD diagnostic codes for Alzheimer’s 
disease (331.0), presenile dementia (290.1), senile dementia (290.0), arteriosclerotic 
dementia (290.4), senile dementia with acute confusional state (290.3), senile 
dementia with paranoia or depression (290.2), dementia other (290.8) or dementia, 
unspecified (290.9). These codes were chosen to identify all patients with dementia 
who were admitted to the hospital.
The hospital records of these patients were located and scrutinised by a 
single observer (G.M). Age at disease onset under age 65 years was used to 
categorise patients as suffering from either presenile or senile dementia.
Information was extracted from each hospital record and patients who fulfilled the 
National Institute of Neurological and Communicative Disorders and Stroke and the 
Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) 
criteria for probable Alzheimer's disease received this diagnosis.
The NINCDS-ADRDA criteria are not unambiguously defined in usable 
form. The interpretation of the criteria used are outlined (Table 1). They were 
strictly applied and any evidence of co-existent systemic or neurological disease 
excluded probable Alzheimer's disease.
An identical information request to that detailed was sent to ISD. A 
comparison was made between the diagnostic categories detailed on the Royal 
Edinburgh Hospital list, the ISD list and those derived after hospital record scrutiny.
(1) The diagnostic codes detailed on the ISD data of patients who fulfilled 
NINCDS-ADRDA criteria for probable Alzheimer’s disease after hospital record
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review were examined. This provided an indirect estimate of diagnostic coding 
errors in the ISD data.
(2) The Royal Edinburgh data list was compared to that from ISD. The two 
data lists should have contained identical information: any unexplained deficiencies 
in the ISD data would indicate incompleteness.
(3) The number of hospital records in which there was insufficient 
documented clinical information to apply the diagnostic criteria were ascertained.
Approval to scrutinise hospital records was obtained from the Privacy 
Committee at ISD and from the Ethical Committee of Lothian Health Board.
Results
The independent hospital register identified 588 hospital records within the 
limits of the data request. All the records were located and scrutinised. 196 of these 
hospital records documented patients with presenile dementia: the rest detailed 
patients with an onset of dementia after age 65 years.
(1) Accuracy of diagnosis.
The diagnostic codes detailed on the ISD data list for these 196 patients are 
detailed in Table 2. Forty-five patients (23%) were wrongly classified under 
diagnostic codes for senile dementia (290.0, 290.2 or 290.3).
Ninety-one of the 196 patients met NINCDS-ADRDA criteria for probable 
Alzheimer’s disease. Such patients should receive two diagnostic codes, 290.1 to 
indicate presenile dementia and 331.0, the specific code for Alzheimer’s disease. 
Their actual diagnostic codes on the ISD data are shown in Table 3. Fifty-seven 
patients with Alzheimer’s disease (64.6%) were coded correctly.
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(2) Completeness of ISD data
Thirty-four patients (17.3%) who had presenile dementia after hospital 
record scrutiny were absent from the ISD data list. Six of these had validated 
presenile Alzheimer’s disease.
(3) Poor quality records
All hospital records were located. Two records (1.0%) contained 
insufficient information to validate the diagnosis of presenile dementia.
Discussion
The first aim of this pilot study was to define the nature of the data request 
to ISD. This aim cannot be divorced from the second to assess the accuracy and 
completeness of data available from ISD.
The study showed that data available from ISD was not accurate. Forty-five 
patients (23%) with verified presenile dementia on hospital record review were 
wrongly coded as having senile dementia. Thirty-four patients (37%) with presenile 
Alzheimer’s disease were incorrectly coded on the ISD data list. The ISD data was 
not complete with 34 patients (17%) with presenile dementia and 6 patients (7%) 
with presenile Alzheimer’s disease not listed.
Coding inaccuracies in general hospital in-patient data between 17% and 
20% have been reported for the diagnostic accuracy of ulcerative colitis, Crohns 
disease and myocardial infarction at ISD (Murchiston et al, 1991, Patel et al, 1976). 
The 7% omission error and 23% diagnostic error found are consistent with these 
findings.
Inaccuracy of diagnosis is outwith the control of ISD and occurs in hospital. 
There were three main reasons for a patient with presenile dementia receiving a 
wrong diagnostic code in the study. Firstly, a patient who presented after age 65 
years but clearly had symptoms of dementia prior to that age was commonly
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diagnosed as senile dementia. Secondly, the diagnosis of senile dementia, if 
mentioned, seemed to "stick" to patients. Some patients with presenile dementia 
admitted to hospital for investigation had senile dementia mentioned and that 
diagnosis then became preferentially accepted. This probably reflects a greater 
general medical and public awareness of senile dementia. Finally, patients with 
presenile dementia admitted to hospital who had no ICD diagnosis clearly and 
unambiguously stated in their hospital record were frequently coded as senile 
dementia.
The diagnostic codes requested for the pilot study were decided upon after 
consultation with experienced psychiatrists, hospital records staff and staff at ISD. 
It is possible that patients with Alzheimer’s disease may have received other 
erroneous codes other than those requested. However, it was not possible to 
scrutinise the hospital records of all patients admitted to the Royal Edinburgh 
Hospital between 1974 and 1988 for logistical reasons.
All patients with Alzheimer's disease were coded as either senile dementia, 
presenile dementia or arteriosclerotic dementia (Table 2). The other diagnostic 
codes failed to identify any patients with Alzheimer's disease (Table 1). Therefore, 
it is unlikely that requesting diagnostic codes outwith those selected would 
significantly improve case ascertainment.
The accuracy of diagnosis of Alzheimer’s disease may vary within 
psychiatric hospitals in Scotland. The Royal Edinburgh Hospital is a teaching 
hospital and several academic staff have a particular interest in dementia. It is likely 
that standards in the diagnosis of presenile dementia in this hospital are at least 
equivalent to, and probably better than, other psychiatric hospitals in Scotland. All 
the diagnostic codes requested in the pilot study would be retained in the main data 
request to ISD to compensate for diagnostic inaccuracies in other psychiatric 
hospitals.
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A further consideration was to define the upper age limit to the data request. 
A proportion of people who first have symptoms of dementia before age 65 years 
will not present to hospital until after that age. Clerical officers at ISD estimated that 
a list of approximately 6,000 hospital records would be generated in Scotland by an 
upper age limit of 73 years. Within the constraints of time and money, this would 
be the maximum number of hospital records that could be scrutinised.
Most people with Alzheimer’s disease die within 8 years of symptom onset 
and present to medical attention several years before this event. The incidence of the 
illness rises exponentially with age. Any increase in the age limit would result in a 
dramatic rise in the number of hospital records that need scrutiny, the majority of 
which would represent people with senile and not presenile disease. Based on these 
considerations an upper age limit of 73 years was set on the data request to ISD.
The final aim of the pilot study, to assess the feasibility of applying 
diagnostic criteria for probable Alzheimer’s disease from information obtained 
retrospectively from hospital record scrutiny, is self-evident from the previous 
discussion. Only two hospital records that detailed patients who suffered from 
presenile dementia contained insufficient clinical information to validate the 
diagnosis. Quality of hospital record recording may vary from hospital to hospital, 
however an unforeseen advantage in reviewing historical records was that, at some 
stage in their prolonged illness, the majority of patients with presenile dementia had 
a detailed history documented and physical examination performed. Reviewing the 
entire natural history of the illness in a large number of patients with presenile 
dementia optimised the ability to apply the diagnostic criteria comprehensively.
This study has highlighted limitations of data available from ISD. If 
appropriate diagnostic codes are requested over 90% of patients with Alzheimer’s 
disease can be successfully identified. This study suggests that the same data 
request to that used would successfully identify the great majority of patients who
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were admitted to psychiatric hospitals in Scotland between 1974 and 1988. The 
study does not validate the data from ISD on a national level.. Further evidence 
from alternative independent data sources would be required to validate the 
completeness of the final study sample. However, the pilot study does support the 
feasibility of defining a sample of people with presenile dementia from ISD.
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METHOD
Population sample
The study data are obtained from retrospective hospital record scrutiny. A 
list of patients aged less than 73 years who were given ICD diagnostic codes for 
Alzheimer’s disease (331.0), presenile dementia (290.1), senile dementia (290.0), 
arteriosclerotic dementia (290.4), senile dementia with acute confusional state 
(290.3), senile dementia with paranoia or depression (290.2), dementia other (290.8) 
or dementia, unspecified (290.9) was received from ISD for all psychiatric hospitals 
in Scotland for the period between 1974 to 1988 inclusive (Pilot Study). The 
psychiatric hospitals included Argyll and Bute, Dykebar, Ravenscraig, Ailsa, 
Dingleton, Crichton Royal, Stratheden, Bellsdyke, Royal Comhill, Bilbohall, 
Kingseat, House of Daviot, Gartloch, Gartnavel Royal, Levemdale, Woodilee, 
Southern General Hospital (psychiatric unit), Craig Dunain, Hartwood, Bangour, 
Herdmanflat, Rosslynlee, Royal Edinburgh, Murray Royal, Royal Liff and 
Sunnyside Royal.
Medical Records Staff within each hospital attempted to locate the hospital 
records of patients listed. All available records were scrutinised by one of two 
experienced observers, G McGonigal (GM) and C McQuade (CM). A third 
observer, L.J.Whalley (U W ), blindly examined a randomly chosen sample of 100 
records
Prior to the start of data entry GM and LJW agreed diagnostic information 
that would be extracted from the hospital records. A patient was accepted if there 
was a documented history of dementia with symptom onset between ages 40 and 64 
years inclusive. The lower age limit was set by the NINCDS-ADRDA clinical 
criteria for probable Alzheimer’s disease, the upper age limit by the arbitrary
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division between presenile and senile disease . The NINCDS-ADRDA criteria 
(Table 1) and a Hachinski score (Table 4) were applied to each patient from 
information documented in their hospital records. All three observers met weekly 
throughout the coarse of the study to standardise interpretation of these criteria.
Patients were classified into three diagnostic groups: (a) ‘Probable’ 
Alzheimer’s disease if they fulfilled the NINCDS-ADRDA criteria for this 
diagnosis and had a Hachinski score less than 5; (b) ‘Broad’ A lzheim er’s disease 
defined after reclassification of all presenile patients using discriminant analysis, this 
group included all those diagnosed as ‘probable’ Alzheimer’s disease (see below); 
and (c) Multi-infarct dementia if a patient had a definite history of at least one 
cerebrovascular accident and a Hachinski score greater than 6.
Completeness of Ascertainment
The study sample would be seriously biased if the assumption that ‘the 
majority of patients with presenile Alzheimer’s disease have been admitted to 
psychiatric hospital at some stage in their illness’ was false. This could result in 
underascertainment of people with Alzheimer’s disease and impair the validity of 
any conclusions. Adequacy of ascertainment was assessed by reference to several 
independent data sources:
(1) In Scotland, death certificates record primary, secondary and tertiary 
causes of death and place of death. This information is stored on computer and 
available from the Registrar General of Scotland. A list of all people aged between 
40 and 64 years inclusive who had died in Scotland after 1974 with any mention of 
Alzheimer’s disease or presenile dementia documented on their death certificates 
was provided. GM scrutinised all available hospital records of people who died in 
institutionalised care outwith psychiatric hospitals to ascertain whether a significant 
proportion were unknown to the psychiatric service. Because patients known to the
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psychiatric service would be less likely to die in other forms of institutionalised care, 
this sample should overestimate the proportion of patients who were unknown to the 
psychiatric service.
(2) People with Alzheimer’s disease are frequently investigated by 
neurologists. A proportion of these patients may never be cared for by 
psychiatrists. To estimate whether this was a significant source of 
underascertainment, two neurology departments in Scotland in which a registry of 
out-patients is maintained were visited (Western General Hospital, Edinburgh and 
Ninewells Hospital, Dundee). Hospital records of all patients aged less than 73 
years for whom a diagnosis of dementia was recorded were scrutinised by GM.
(3) All Chief Administrative Medical Officers in Scotland were contacted 
and their advice sought concerning the nursing management of patients with 
presenile dementia. This matter was discussed in local family doctor committees 
throughout Scotland. Similar advice was requested from medical advisers to the 
Mental Welfare Commission for Scotland
(4) In Grampian, all in-patient and out-patient psychiatric patient events have 
been notified to the Grampian Psychiatric Case Register since 1963. This register 
was used to assess whether any patient with presenile Alzheimer’s disease was 
investigated by a psychiatrist as an out-patient but was never admitted to hospital.
Statistical methods
(a) Can current clinical criteria used to diagnose Alzheimer’s disease be 
improved and modified for specific use in epidemiological research?
All patients with presenile dementia who had undergone neuropathological 
examination were identified within the study population. Each patient record was 
assigned a clinical diagnosis of either ‘probable’ Alzheim er’s disease, and classified 
as group 1, or ‘other dementia type’ and classified as group 2 (this group included
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patients with multi-infarct dementia) on the basis of the NINCDS-ADRDA criteria 
alone and, also, by the combination of the NINCDS-ADRDA criteria with the 
Hachinski score before the results of neuropathological examination were known.
Neuropathological diagnosis was obtained from the discrete 
neuropathological record of each patient. A diagnosis o f Alzheimer’s disease was 
accepted if there was documented proof of senile plaques and neurofibrillary tangles 
present in the hippocampus (Ball, 1977, Ball et al, 1985) in the absence of any 
evidence of an ischaemic vascular lesion (Molsa et al, 1985). These criteria were 
applied to the detailed neuropathological records by GM, who was blind to the 
clinical diagnosis at the time of scrutiny. This neuropathological diagnosis was the 
‘gold-standard’ to which diagnoses based on clinical criteria applied directly and 
after discriminant analyses were compared. The clinical criteria were the selected 
variables for discriminant analyses (Table 5).
Discriminant analyses derives a linear composite, the discriminant function, 
which maximally discriminates between groups. A discriminant score which 
maximises the F ratio of the between-group and within-group mean squares was 
provided for each patient. The discriminant function was derived by the direct 
method which simultaneously enters all variables that pass tolerance criteria (set at 
0.001). The discrimination achieved by this analyses (Analyses A) was compared 
with the results of two further discriminant analyses, one with 11 randomly selected 
patients from group 1 removed (Analyses B), the other with 18 randomly selected 
patients from group 1 and 13 randomly selected patients from group 2 removed 
(Analyses C). These further analyses provided a test of ‘spuriousness’ of the 
results of the first analyses (Whalley et al.,1989).
Specificity, sensitivity and diagnostic accuracy of the clinical criteria before 
and after discriminant analyses were calculated (Fig 1).
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Interobserver reliability in the application of the clinical criteria was assessed 
using Cohen’s kappa statistic. This is a statistic that is relatively unaffected by the 
prevalence of disease. The two main observers, GM and CM, were compared to the 
third, LJW, who acted as a standard. No direct comparison was made between GM 
and CM. No neuropathological ‘gold-standard’ was involved in this analysis.
(b) What is the incidence rate of presenile Alzheimer’s disease in Scotland?
and
c) Is gender a risk factor in presenile Alzheimer’s disease?
The incident date was that of first presentation to hospital services, either as 
an in-patient, out-patient or domiciliary consultation. Denominators for incidence 
calculations were taken from the 1981 census and used to estimate the ‘at risk’ 
population aged 40 to 64 years. 95% Confidence Intervals were calculated with 
exact error factors for Poisson mean for numbers less than 30 and with the 
asymptotic error factor approximation for larger numbers. Mantel-Haenszel 
weights were used for the summary risk ratios.
(d) What is the natural history of presenile A lzheimer’s disease?
Age at first presentation to specialist care was used to age the sample. Date 
and place of death was ascertained from death certificates available from the 
Registrar General for Scotland. Duration of survival was calculated from these two 
dates.
(i) Censured data.
Probability of survival in patients with ‘probable’ Alzheimer’s disease was 
calculated for the total sample by the life-table method (follow-up through to 1 July 
1992). Additional life-tables were calculated for males and females, for those who 
presented before and after 1981 and for those who presented before and after age 52
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years. Survival curves in each of these paired groups were compared by the log 
rank test.
(ii) Actual data.
In those patients who had died in the follow-up period, actual survival 
duration was compared in males and females, those with Alzheimer’s disease who 
presented before and after age 52 years and those who presented before and after 
1981. This analysis was performed to examine the consistency of the life-table 
analysis. In addition, survival duration in those who died in psychiatric hospital was 
compared to those who died at home and in general hospitals. The distribution of 
survival time was positively skewed in all groups. Logarithmic transformation 
normalised the distribution and group geometric means were tested using unpaired t 
tests.
Ethics
Ethical Approval to scrutinise hospital records was obtained from Ethics 
Committees of all Health Boards in Scotland and from the Privacy Committee of the 
Scottish Home and Health Department.
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RESULTS
ISD identified 6581 patients. 5874 hospital records were located and 
scrutinised (707 records were lost or inadquate) of which 1679 were records that 
documented patients with verified presenile dementia. Of these 1217 patients were 
aged 40 to 64 years at presentation to hospital services.
(a) Can current clinical criteria used to diagnose Alzheimer’s disease be 
improved and modified for specific use in epidemiological research?
(i) Validity of clinical diagnosis before and after discriminant analysis vs 
neuropathological ‘gold standard’.
Sixty-one patients (3.6%) with presenile dementia underwent 
neuropathological examination. Thirty-six patients had neuropathological 
confirmation of pure Alzheimer's disease (true group 1); 16 patients had no evidence 
of this disease at post-mortem and 9 patients had mixed pathology (true group 2). 
Criteria confirming the presence of cognitive impairment failed the tolerance test: all 
other criteria passed. Standardised canonical discriminant function coefficients are 
given for each of the three initial analyses (Table 5). The classification of patients 
comparing the clinical diagnosis to that derived from analysis A are shown (Table 
6). Analysis B correctly classified 22 patients with pure Alzheimer's disease (88%) 
and analysis C 17 patients (94.4%).
The specificity, sensitivity and diagnostic accuracy of clinical and discriminant 
classifications are shown (Table 7). The discriminant classification was more 
accurate than clinical classification using solely NINCDS-ADRDA criteria and also 
by clinical classification by these criteria used with the Hachinski Score.
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(ii) Reliability of clinical criteria used to diagnose Alzheimer’s disease.
One hundred hospital records were scrutinised by U W . Sixty of these 
records had previously been reviewed by GM. Kappa values of 0.72 and 0.61 were 
obtained when comparing GM and CM to LJW.
(b) What is the incidence rate of presenile Alzheimer’s disease in Scotland?
and (c) Is gender a risk factor in presenile Alzheimer’s disease?
Scrutiny of 1217 hospital records identified 569 broad cases of A lzheimer’s 
disease (of which 317 were probable cases) and 267 cases of multi-infarct dementia. 
If each psychiatric hospital had the same proportion of missing or inadequate 
records (317 / 5784 = 5.4%) then about 38 cases of probable A lzheim er’s disease 
(5.4% of 707) were omitted because of lost or inadequate records.
Tables 8 and 9 give the age-sex specific incidences and female to male risk 
ratios for probable and broad Alzheimer’s disease. Increasing age and female 
gender were associated with an increased incidence of Alzheimer’s disease. The 
summary sex risk ratios for probable and broad Alzheimer’s disease were similar. 
Crude division of overall incidence by 15 (number of years studied) gave annual 
rates of 1.5 / 100 000 and 2.7 / 100 000 for probable and broad Alzheimer’s disease 
respectively. These compare with the actual rates of 1.6 (95% C.I. 1.0 to 2.6) and 
3.5 (2.6 to 4.7) per 100 000 for probable and broad Alzheimer’s disease for the 
1981 census year. Females had significantly less risk of multi-infarct dementia 
compared to males (Table 10).
(d) What is the natural history of presenile Alzheimer’s disease?
Of the 317 people who fulfilled criteria for ‘probable’ Alzheimer’s disease, 
244 (77.0%) had died before the end of the follow-up period: 193 (79.1%) in
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psychiatric hospitals, 31 (12.7%) in general hospitals, 16 (6.6%) at home and 4 
(1.6%) in nursing homes.
(i) Censured survival data.
Overall five year survival was 51.2%, decreasing to 17.3% at ten years 
(Figure 2). Descriptive data on males and females are shown together with curves 
that describe and contrast survival (Table 11, Figure 3). Males had a significantly 
shorter duration of survival compared to females (p < 0.025). The ratio of death 
rates in males to those in females was 1.4 (Table 11).
No significant difference in survival duration was found in those who 
presented before and after age 52 years and in those who presented before and after 
1981.
(ii) Actual survival data
The findings detailed were consistent in the group of patients who had died 
before the end of follow-up (Table 12). Females survived 1.3 times longer than 
males (C.I. 1.04 - 1.61; p < 0.02). Place of death, age at presentation and year of 
presentation did not significantly affect survival duration.
Completeness of Ascertainment
(1) Data from the Registrar General of Scotland identified 199 patients who 
had died in instituitions other than psychiatric hospitals and who were not 
ascertained in the study sample. These patients hospital records were requested, 89 
(44.7%) were located. Nine of the records scrutinised documented patients with 
‘probable’ Alzheimer’s disease, 3 of whom had not been previously admitted the 
psychiatric hospital (the other 6 patients presented to psychiatric hospital prior to 
1974).
(2) One hundred and twenty nine neurology outpatient records were 
reviewed. Twenty-four patients suffered from ‘probable’ Alzheimer’s disease, 20
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of whom were already known to the psychiatric service. The remaining 4  presented 
to neurology outpatients after 1983.
(3) Anecdotal assurance was received from all Chief Administrative Medical 
Officers and from medical advisers to the Mental Welfare Commission for Scotland 
that the vast majority of patients with presenile dementia were cared for in the 
psychiatric health services.
(4) The Grampian Psychiatric Case Register had no record of any patient 
with presenile dementia in North-East Scotland who may have had presenile 
Alzheimer’s disease but was never admitted to psychiatric hospital.
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TA BLES AND FIG U R ES
Table  1. The interpretation o f the N1N C D S-A D RD A  criteria for  probable 
A lzheim er's  disease used in the study.
C R IT E R IA IN T E R PR E T A T IO N
History o f  progressive m em ory  
loss.
As a dom inant initial feature
C onfirm ed loss o f  at least 2 areas of 
cognitive function
D ocum ented  from patient or 
hospital record
Insidious onset S ym ptom s over a period o f at least 3 
m onths
Mentally alert Alert at time o f  sym ptom  onset and 
presentation.
No co-existent systemic disease Absence o f alcoholism, ischaemic 
vascular disease, diabetes etc
No co-existent brain disease Absence of head injury, neoplasm, 
cerebro-vascular events etc
Investigations performed to exclude 
o ther causes o f dementia
Thyroid  function tests, normal M CV 
and syphilis  serology.
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Fable 2. ICD diagnostic codes docum ented  in 196 hospital records o f  patients with 
presenile dementia.
ICD  C O D E  A N D  D E F IN IT IO N N U M B E R  (% )
290.1 Presenile dem entia 81 (41.3)
290.0 Senile dem entia 3 7 ( 1 8 .9 )
290.4 Arteriosclerotic dementia 2 8 (1 4 .3 )
290.8 D em entia-other 2 2 (1 1 .2 )
290.9 Dem entia-unspecified 2 0 (1 0 .2
290.3 Senile dementia, acute confusion 5 ( 2 .6 )
290.2 Senile dementia, depressed / paranoid 3 ( 1 .5 )
T able 3. ICD diagnostic codes docum ented  in 91 hospital records o f patients with 
presenile Alzheimer's  disease.
IC D  C O D E  A N D  D E F IN IT IO N N U M B E R  ( %)
331.0  (and 290.1) A lzheim er's  disease 5 7 ( 6 2 .6 )
290.0 Senile dementia 18 (1 9 .8 )
290.1 (not 331.0) Presenile dem entia 13 (14.3)
290.4 Arteriosclerotic dementia 3 (3.3)
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Table 4. T he Hachinski score. A score less than five suggests A lzh e im er 's  disease, 
greater than six, multi-infarct dementia.
C r ite r ia S co re
Abrupt onset o f  sym ptom s 0 if no; 2 if yes
Stepwise deterioration 0 if no; 1 if yes
Fluctuating coarse 0 if no; 2 if yes
Nocturnal confusion 0  if no; 1 if yes
Preservation o f  personality 0  if no; 1 if yes
Depression 0 if no; 1 if yes
Somatic complaints 0  if no; 1 if yes
Emotional incontinence 0 if no; 1 if yes
History o f  hypertension 0 if no; 1 if yes
History o f stroke 0 if no; 2 if yes
Evidence of arteriosclerosis 0  if no ;l  if yes
Focal sym ptom s 0  if no; 2 if yes
Focal signs 0 if no; 2 if yes
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T able 5. Standardised discriminant function coefficients o f  clinical criteria used to 
d iagnose pure Alzheim er's  disease.
C RITER IA
(V A RIA BLE)
A NA LY SIS A 
(n = 6 1 ; 3 6  vs 25)
A N A L Y SIS  B
(n=50; 25 vs 25)
A N A L Y S IS  C
(n=30: 18 vs 12)
HACHINSKI SCORE 0.55 0 .48 0 .5 5
CO-EXISTENT BRAIN 
DISEASE
0 .54 0.61 0 .6 8
CO-EXISTENT 
SYSTEMIC DISEASE
0.49 0 .44 0 .0 0
HISTORY OF 
EPILEPSY
-0.26 -0.38 -0.17
RESULTS OF 
INVESTIGATIONS
-0.13 -0.11 0.1 1
MENTALLY ALERT 
AT PRESENTATION
0.07 0.05 -0 .10
INSIDIOUS ONSET 0.06 0.13 0 .00
HISTORY OF 
MEMORY LOSS
-0.03 -0 .04 -0 .09
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Table 6. Classification o f 61 patients with dem entia  according to clinical
diagnosis and discriminant classification.
Predicted diagnostic group: 
No.
(% correctly classified)
Neuropathological
D iagnosis
n Clinical
Classification
Discri minant 
Classification
Alzheimer's 
D isease (G roup 1)
36 2 2 (6 1 .1 % ) 3 2 ( 8 8 .9 % )
O ther  type o f  
D em entia  (Group 2)
25 2 2 (8 8 .0 % ) 1 9 (7 6 .0 % )
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Table 7. Specificity, sensitivity and diagnostic accuracy o f clinical and
discriminant classification o f patients with presenile dem entia who had 
neuropathological examination.
CLINICAL CLASSIFICATION DISCRIMINANT CLASSIFICATION
Criteria Specificity
(%)
Sensitivity
(% )
Accuracy
(% )
Specificity
(% )
Sensitivity
(% )
Accuracy
(% )
NINCDS-ADRDA 
AND HACHINSKI
61.1 88 .0 72.1 76 .0 88 .9 83 .6
NINCDS-ADRDA
ALONE
88.0 61 .0 72.1 80 .0 75 .0 77.1
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Table 8. Incidence (95% confidence intervals) pe r  100 000  at risk population of 
cases o f  probable A lzh e im er 's  disease presenting in Scotland 1974-1988.
Age / years Males Females All Female to male 
risk ratio
40 -4 4 0.7 2.0 1.4 2.9
4 5-49 7.2(3.4-13.2) 8 .9(4 .7-15 .2) 8.1 1.2
5 0 -5 4 20.1(13.9-29.1) 3 4 .7 (26 .5 -45 .4 ) 27 .6 1.7
55-59 29.6(21.8-40.3) 48 .9 (39 .0 -61 .4 ) 39 .7 1.7
60-64 27.1(19.1-31.5) 46 .8 (36 .5 -59 .9 ) 37 .8 1.7
Total 16.5(13.8-19.8) 28 .2 (24 .5-32 .4) 22 .6 (20 .2-25 .2) 1.7*
* M antel-Haenszel sum m ary estimate
Table 9. Incidence (95% confidence intervals) per 100 000  at risk population of 
cases o f  broad A lzh e im er 's  disease presenting in Scotland  1974-1988.
Age / years Males Females All Female to male 
risk ratio
40 -4 4 0.7 5.5 3.1 7.7
45-49 10.1(5.5-16.9) 13.7(8.1-21.1) 11.9 1.4
5 0-54 29.4(21.7-39.9) 55 .3 (44 .6 -68 .6 ) 42 .8 1.9
5 5-59 44.8(35 .0-57 .5) 91 .2 (83 .7 -99 .3 ) 69.1 2.0
6 0-64 62.0(55.1-80.2) 95 .8 (87 .8 -104 .) 80 .4 1.5
Total 28.1(26.1-30.2) 52 .0 (49 .4 -54 .7 ) 40 .5 (38 .9 -42 .3 ) 1.8*
* M antel-Haenszel sum m ary estimate
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Table 10. Incidence (95% confidence intervals) per 100 000  at risk population of 
cases o f  multi-infarct dementia identified from psychiatric hospital records in 
Scotland 1974-1988.
Age / Years M ales Females
40-44 5.0 2 .0
45-49 7.2 3.4
50-54 17.2 8.7
55-59 34 .0 20.5
6 0-64 70 .8 33 .6
Total 25 .1 (23 .3 -27 .1 ) 13.4(12.1-14.8)
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Table  11. Characteris tics  o f  the total study sam ple w ho had ’p robable ' A lzh e im er 's
disease.
G e n d e r N u m b e r M e d ia n  a g e  in  
y e a r s  ( Q 1-Q 3 )
F iv e  y e a r  
s u r v iv a l
R e la t iv e  d ea th  
ra te
Male 1 11 5 9  (5 5 -6 3 ) 43.3% 1.23
Female 2 0 6 5 9 ( 5 6 - 6 3 ) 56.2% 0 .8 9
Table  12. Characteristics o f those people with ’probable ' A lzh e im er 's  disease w ho 
died in the follow-up period.
G e n d e r N u m b e r M e d ia n  a g e  in  
y e a r s  ( Q 1-Q 3 )
M e d ia n  s u r v iv a l  
in  y e a r s  ( Q 1 Q 3 )
Males 93 60  (56-63) 3.8  (2.2-5.9)
Females 151 6 0 (5 7 - 6 3 ) 4 .7  (2.8-6.7)
Table 13 Guidlines for interpreting kappa values (Landis  and Koch, 1977).
K appa Range Level o f agreement
0 .0 0  - 0 .20 slight
0.21 - 0 .4 0 fair
0.41 - 0 .6 0 moderate
0.61 - 0 .8 0 substantive
> 0 .81 almost perfect
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Figure 1. Definition o f terms. A D  signifies A lzheim er's  disease.
N E U R O P A T H O L O G IC
D IA G N O S IS
A D  N O T  A D
AD
C R IT E R IA  /
D IS C R IM IN A N T
D IA G N O S IS
N O T  A D
a b
c d
SPE C IF IC IT Y  = d /b+d 
SEN SITIV ITY  = a/a+c
D IA G N O S T IC  A C C U R A C Y  = a+ d /a+ b+ c+ d
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Figure 2. Survival o f  317  people with 'p robab le ' A lzh e im e r 's  disease.
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Figure 3. Survival by gender in 317  people with 'p ro b ab le 'A lz h e im e r 's  disease.
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Figure 4. Possible patterns of health care provision to patients with Alzheimer's disease.
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Fieure 5. Three areas of research in Alzheimer's disease with some main outcome measures.
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DISCUSSION
(a) Can current clinical criteria used to diagnose Alzheimer’s disease be 
improved and modified for specific use in epidemiological research?
Discriminant analysis based on the Hachinski Score and the NINCDS- 
ADRDA criteria correctly classified 51 patients (83.6%) with presenile dementia 
(Tables 6 and 7). This compares to 44 patients (72.1%) correctly classified who 
received diagnoses directly from both clinical criteria. Analysis that used only the 
NINCDS-ADRDA criteria classified 47 patients (77.1%) correctly compared to 44 
patients (72.1%) diagnosed clinically (Table 7). The variables of highest 
discriminating value were the Hachinski Score, the presence of co-existent 
neurological disease and the presence of co-existent systemic disease (Table 5).
Discriminant analysis is a statistical method for testing a classificatory 
system (Kendell, 1975, Moran, 1966). The validity of any distinction found 
between groups rests upon the analysis meeting four criteria. Firstly, the co- 
variance matrices for each of the diagnostic groups must be equal to avoid spurious 
results (Kendell and Post, 1973). Secondly, the number of subjects in the analysis 
needs to be more than the product of the number of variables and the number of 
groups. Thirdly, the two diagnostic categories must have a bimodal distribution with 
a 'point of rarity' between groups. This was demonstrated between the ‘gold- 
standard’ Alzheimer's disease group 1 and group 2: 11.1% misclassified after 
analysis A, 12% after analysis B, 5.6% after analysis C. Fourthly, the results should 
be replicated on an independent data set. The first three criteria were met but the 
latter was not possible in the present study.
The ability of clinical and discriminant analysis to correctly classify patients 
was evaluated by reference to the 'gold standard' of neuropathological diagnosis.
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However, the diagnostic accuracy of clinical criteria is influenced by the 
neuropathological criteria used to define Alzheimer's disease (Chapter - Definition 
of Alzheimer’s disease). Neuropathological examination is not routinely performed 
as part of a post-mortem examination in Scotland. When conducted detailed results 
are documented by the pathologist. This study used accepted neuropathological 
criteria that could be directly and easily applied to the information contained in 
neuropathological records. The criteria used were selected on this principal; other 
neuropathological criteria may have produced different results. Standard 
neuropathological criteria are needed to avoid this source of bias in the future. The 
unsatisfactory situation at present is that all studies which directly validate clinical 
criteria to diagnose Alzheimer’s disease can be criticised on the ‘gold-standard’ 
criteria used. However, this methodological limitation should not exclude attempts 
to improve clinical and research practice.
In classifying patients with mixed dementia into group 2 there were no 
patients in which the diagnosis reached after neuropathology record scrutiny by 
GM. differed from that of the pathologist, even though GM was blind to the 
reported diagnosis. It is unlikely, therefore, that neuropathological diagnostic error 
has biased the results.
The exclusion of patients with both histological features of Alzheimer's 
disease and multi-infarct dementia (i.e.mixed dementia) from the Alzheimer's 
disease group limit the conclusions of the study to the differentiation of 
uncomplicated disease from all other types of dementia. This is problematical. 
Patients who have mixed dementia have a 'degree' of Alzheimer's disease but are 
excluded from that diagnostic group. This limitation is appreciated but this study 
was not able to define all patients with uncomplicated presenile Alzheimer's disease 
by strict application of inclusive and exclusive clinical criteria. The diagnostic
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accuracy of the criteria would have been further reduced if patients with mixed 
dementia had been included in group 1.
This study used a large retrospective epidemiological survey to define 
patients in which neuropathological information was available. These 61 patients 
were a selected group and represent 3.6% of the total sample of people with 
presenile dementia who were ascertained. Major determinants of whether a patient 
had a post-mortem performed were: place of death, local availability of 
neuropathological services, individual practice of psychiatric consultants, degree of 
certainty in diagnosis ete.
The discriminant analysis described does not differentiate between all 
categories of Alzheimer’s disease and all other forms of dementia. This is clearly 
true if people with mixed dementia are not included in the Alzheimer’s disease 
group. Also, it is unlikely that the ‘gold-standard’ sample of patients with 
uncomplicated Alzheimer’s disease represent a random, homogeneous sample of the 
population with presenile Alzheimer’s disease. The low post-mortem rate in the 
presenile population would make this a difficult argument to sustain. The 
discrimination is between a sub-sample of patients with Alzheimer’s disease and all 
other forms of dementia, which may include other people with various ‘degrees’ of 
Alzheimer’s disease. As clinical criteria to diagnosis Alzheimer’s disease do not 
define all patients with the illness, but rather sub-samples of people with various 
degrees of certainty in the diagnosis, the use of discriminant analysis on this 
selected group remains valid. The usefulness of this statistical technique would be 
greater if the post-mortem rate were improved.
Diagnostic limitations imposed on investigators in epidemiological research 
in Alzheimer’s disease have been highlighted. No clinical criteria can accurately 
define all patients with this illness in the community. Discriminant analysis may be 
a method by which diagnostic accuracy can be improved. The technique is limited
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by the low post-mortem rate in people with presenile dementia and the lack of 
consensus as to what constitutes definite A lzheimer’s disease. The results reported 
are encouraging, but must be validated on an independent data set before the use of 
the technique can be recommended. It is possible that the results reported are due to 
chance alone and the consistency of the method needs to be tested.
Reliability of clinical criteria is an important consideration in improving the 
quality of epidemiological research in Alzheimer’s disease. Poor reliability 
suggests poor validity, however it is possible to have a high degree of agreement 
amongst observers but for them all to be wrong. Subjective guide-lines for 
interpreting kappa values have been proposed (Table 12 - Landis and Koch, 1977).
Most clinical judgements vary between clinicians. Kappa values for 
interpreting electrocardiograms (normal or abnormal) have been reported at 0.70, 
reporting on intravenous pyelograms (presence or absence of pyelonephritis) at 0.27 
and in deciding, after clinical examination, whether a heart valve lesion was present at 
0.60 (Koran, a and b, 1975). Kappa values between 0.53 and 0.74 have been 
reported for the diagnosis of possible and probable A lzheimer’s disease using the 
NINCDS-ADRDA diagnostic criteria (Kukull, a, 1990).
This study reports kappa values of 0.72 and 0.61 using the interpretation of 
the NINCDS-ADRDA criteria described (Table 1). These are consistent with those 
previously reported. GM is a physician trained in general and geriatric medicine, 
CM is a trained Registered General Nurse and Psychology Graduate and U W  is a 
psychiatrist with a particular interest in dementia. The higher kappa value between 
physician and psychiatrist may reflect greater experience in diagnostic decision 
making. The level of agreement between nurse and psychiatrist show that the 
proposed criteria can be successfully applied by people less experienced in the 
diagnosis of dementia, and that further improvements in interobserver variation 
could be made with increased training and standardisation.
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(b) What is the incidence rate of presenile Alzheimer’s disease in Scotland?
and
c) Is gender a risk factor in presenile A lzheimer’s disease?
The reported rates for probable and broad Alzheimer’s disease are minimum 
estimates of the true incidence. The data request may have omitted 6.5% of cases 
(Pilot Study), and a further 5.4% may have been lost because of inadequate hospital 
records. These errors are small compared with the effects of changes in diagnostic 
criteria: rates in the broad classification are appproximately double those in the 
probable category. Although the method used to define broad cases is novel and 
needs to be validated, the main findings are consisent in both categories of 
Alzheimer’s disease. Female gender was significantly associated with the risk of 
Alzheimer’s disease, though small numbers in the under 55 year age group make 
interpretation of a gender effect inappropriate.
Date of first presentation to specialist hospital care was chosen as the 
incident date. It is determined by referral practices of patient to General Practitioner 
and of General Practitioner to hospital. These practices will vary according to 
individual patients, doctors and the local availability of health care. Patients aged 64 
years with mild memory failure may accept the deficit more readily than those aged 
40 years. Referral thresholds of General Practitioner will vary according to previous 
experienced in investigating those with dementia and be determined by the degree of 
illness and patient’s age. Hospital waiting times will also influence the time between 
symptom onset and presentation to hospital services.
The main advantage in using the date of presentation to hospital care as the 
incident date is that it is easily and reliably obtained from hospital record scrutiny.
It is also directly relevant to those who plan diagnostic services for people with 
presenile Alzheimer’s disease. The alternative incident date would be date of
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symptom onset. This date was not precisely documented in psychiatric hospital 
records, is subject to recall bias and, in a substantial number of cases, was unknown.
Female gender has become a recognised risk factor for the development of 
Alzheimer’s disease after age 65 years. To my knowledge, a significant association 
between gender and A lzheim er’s disease with an onset before age 65 years has not 
been described. Several studies have found a small excess of female patients with 
early onset Alzheimer’s disease in population studies, but the difference did not 
reach statistical significance (Treves et al, 1986, Molsa et al, 1982, Sulkava et al, 
1983). This apparent inconsistency between female gender as a risk factor for 
Alzheimer’s disease with an onset after age 65 years and that with an onset earlier 
was unexplained, but suggested an interaction between gender and the ageing 
process.
This study supports the association between female gender and an increased 
risk of presenile Alzheimer’s disease. However, two other explanations for the 
association are possible. Firstly, variation in the utilisation of health services 
between the sexes could lead to an erroneous association. Doctors and other health 
care professionals may be more likely to refer females with memory impairment for 
specialist advice and/or male carers may not maintain their female relatives with 
dementia in the community for as long as female carers. If these assumptions are 
true, a similar excess of female sufferers with other forms of dementia would be 
expected. This was not the situation in those patients admitted to psychiatric 
hospital with multi-infarct dementia (Table 10).
Patients categorised as multi-infarct represent a distinct clinical sub-group 
within the study sample, but it is debatable whether they accurately represent all 
patients with this illness in the population. The point of health service contact for 
patients with cerebrovascular disease and dementia is very variable and dependent on 
a number of factors not evaluated in this study (eg, which pathology appeared
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initially, the relative dominance of symptoms, ete). The inverse association between 
female gender and the reported incidence rate of multi-infarct dementia, in the sub­
sample of patients who entered the psychiatric hospital service, would suggest that 
variation in the use of health care services does not explain the association between 
female gender and Alzheimer’s disease.
Secondly, diagnostic error may explain the association. This study has 
described an association between male gender and the clinical diagnosis of multi­
infarct dementia in a sub-sample of patients admitted to psychiatric hospital. This 
study does not conclude that a generalisable association exists because the study 
was designed to ascertain people with Alzheimer’s disease and not this specific type 
of dementia. However, a high proportion of people with multi-infarct dementia have 
co-existent neuropathological features of Alzheimer’s disease. This will result in 
systematic underascertainment of men with Alzheimer’s disease which may be of 
sufficient magnitude to cause a spurious association between female gender and 
Alzheimer’s disease.
This study supports an association between female gender and clinical 
Alzheimer’s disease. Deficiencies in clinical diagnostic techniques prevent 
conclusive evidence from being obtained; male patients with Alzheimer’s disease 
may be differentially misclassified as other forms of dementia. If the association 
can be confirmed then the answers to two related questions will herald a major 
breakthrough in understanding the pathogenesis of Alzheimer’s disease: what is it 
about being female that increases the risk of this disease?, or alternatively, what is it 
about being male that protects against the development of the illness?
(d) What is the natural history of presenile Alzheimer’s disease?
Five year survival in the sample of people with probable Alzheimer’s disease 
was 51.2% and females with the illness lived approximately 1.4 times longer than
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males. Age at presentation to specialist care ancd place of death did not significantly 
alter survival duration. There was no evidence that survival duration had altered over 
the period of study. The consensus between cemsured and actual survival data 
indicated that those people with presenile A lzheim er’s disease ascertained in the 
study but w ho were still alive at the end of follo>w-up did not represent a distinctive 
sub-group of individuals with the disease.
Age at presentation to specialist care wais chosen to estimate survival 
duration because it provides prognostic informaition that is relevant to specialists 
who council relatives and patients with A lzheim er’s disease. Also, this date was 
consistently and reliably obtained from hospitall record scrutiny. However, the date 
is not an unbiased surrogate for time of disease' onset and its use excludes a variable 
proportion of the natural history of the illness. T he difference in the survival 
characteristics between males and females repoirted could be explained by variations 
in the referral practice of primary care physiciams. They may refer or even detect the 
illness earlier in females compared to males.
In developed countries, death rates are consistently higher in males 
compared to females in all age groups because of the influence of a number of 
common diseases which have higher incidence rates in males. The diagnostic 
criteria used to define people with ‘probable’ A lzheim er’s disease excluded those 
with other co-existent diseases which included those illnesses most responsible for 
the excess of mortality in males (ischaemic heairt disease, peripheral vascular disease, 
lung carcinoma, cerebro-vascular disease ete). T he excess mortality reported in 
males with presenile Alzheimer’s disease is nott explained by increased incidence 
rates of other diseases in this gender. The studly sample was ‘corrected’ for this 
potential bias by the clinical diagnostic criteria;; adjusting the figures for expected 
mortality in males and females in Scotland is, therefore, inappropriate.
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It is unlikely that the natural history of A lzheimer’s disease is altered by not 
being admitted to psychiatric hospital. Certainly, terminal care provision in an 
institution other than a psychiatric hospital did not influence survival duration. It is 
a reasonable assumption that the reported findings give an accurate and a 
generalisable description of the natural history of presenile Alzheimer’s disease that 
are relevant to all professionals who council those with the disease.
Comparisons between the findings of this study and other studies are 
difficult due different methodology and age ranges. The observation that age at 
presentation did not alter survival duration is consistent with several other studies 
(Drachman et al 1990, Huff et al, 1987). Male gender has been associated with a 
shorter duration of survival in Alzheimer’s disease (Barclay et al, 1985, Berg et al, 
1988), however this has not been a consistent finding (Drachman et al 1990, 
Diesfeldt et al, 1986). The finding that females live longer after they have presented 
to specialist care is of obvious importance to those who plan health care services for 
dementia sufferers.
The natural history of presenile Alzheimer’s disease has been described.
The detailed information should help professionals who care for those people whose 
lives are affected by Alzheimer’s disease. The findings are also recommended to 
health service planners who should note the increased survival duration in females 
with this disease. The differential effects of gender on survival duration in presenile 
Alzheimer’s disease needs further study.
Completeness of Ascertainment
The central assumption in the sampling method is that the majority of 
patients with Alzheimer’s disease with symptom onset aged less than 65 years are 
admitted to psychiatric hospital and are, therefore, listed in centrally available 
psychiatric health service returns (Pilot Study). This assumption needs to be
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considered in some detail. There are several theoretical pathways of health care 
provision that could result in serious underascertainment of people with this illness 
(Figure 4).
People with Alzheimer’s disease may never present to medical attention, but 
die in the community either undiagnosed or cared for by relatives who have never 
sought support (Pathway A, Figure 4). The number of such patients will be small 
because of the insidious course, the behavioural disturbances and the distress 
associated with the illness. In addition, people with symptoms of memory 
impairment in early life are more likely to present to medical care than accept 
negative stereotypes of memory failure and ‘normal’ ageing. However, some 
people with mild symptoms and a slowly progressive disease may remain 
independent until death. This situation is analogous to many other medical illnesses 
which do not produce sufficient distress for people to seek medical help, eg silent 
ischaemia in atheromatous heart disease, asymptomatic large bowel cancer ete. Such 
individuals are at one extreme of the disease distribution and, although important in 
their own right, will not significantly alter the reported incidence rates of 
Alzheimer’s disease.
People with Alzheimer’s disease may present to their General Practitioner 
(GP), but not be refered further along the health care pathway (Pathway B, Figure 
4). As shown, GP’s have a crucial, central role in deciding the pattern of future 
health care delivery to patients with Alzheimer’s disease. They were not included in 
the sampling frame for a number of reasons. Firstly, local family doctor committees 
throughout Scotland discussed how they managed patients with presenile 
Alzheimer’s disease and reported that the great majority of such patients were 
referred to psychiatrists or neurologists. Secondly, colleagues in Newcastle, whose 
aim was to estimate the prevalence of presenile dementia in a defined geographical 
area, found that approaches directly to GP’s did not detect any patients with
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presenile dementia who were not already known to the hospital services. Finally, the 
quality of GP record keeping is variable and most records are destroyed after a 
patient dies. The retrospective design of the study would require G P’s to remember 
patients with presenile Alzheimer’s disease because few maintained a diagnostic 
index for the time period between 1974 to 1988. Such an approach is unscientific 
and would be justifiably criticised.
Patients with Alzheimer’s disease could be referred for out-patient specialist 
investigation, but never be admitted to hospital (Pathway C, Figure 4). Two 
independent data sources were used to examine whether significant numbers of 
patients followed this course. Only 3% (4 / 129) of patients with dementia who 
attended two neurology out-patient departments had not been admitted to psychiatric 
hospital. These patients presented after 1983 and had not developed major social 
and behavioural problems at the time of hospital record scrutiny. It is reasonable to 
postulate that these patients will be referred and admitted to psychiatric hospital as 
their illness deteriorates. In Grampian, no patient who attended psychiatric out­
patient and received a diagnosis of presenile Alzheimer’s disease was not admitted 
to psychiatric hospital. Although the evidence presented may reflect local practice 
by neurologists in Dundee and Edinburgh and psychiatrists in the North-East of 
Scotland it was consistent with advice received from Chief Administrative Medical 
Officers, medical advisers to the Mental Welfare Commission and experienced 
general psychiatrists in Scotland.
Patients with Alzheimer’s disease could be admitted to general hospitals and 
never be detailed on psychiatric hospital returns (Pathway D, Figure 4). One- 
hundred and ninety nine non-psychiatric hospital records were requested, these 
included 169 records from district general or teaching hospitals and 34 from cottage 
or private hospitals. Over half of these records had been destroyed after the patient 
had died and could not be scrutinised. Of the 89 records scrutinised, three patients
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(3.4%) had verified ‘probable’ Alzheimer’s disease but had not been admitted to 
psychiatric hospital. Most patients who die in general institutions have been 
admitted to psychiatric hospitals at some stage of their illness. The sampling 
method used to validate psychiatric hospital data could not be expanded to general 
hospital returns because of the policy of general hospital record destruction.
This thesis assumes that the majority of patients with Alzheimer’s disease 
are detailed on psychiatric hospital returns (Pathway E, Figure 4). Incidence rates of 
two classifications of Alzheimer’s disease calculated using this study sample are 
consistent with results reported by other investigators who used different case 
ascertainment methods. As indicated, there are a small number of people with 
Alzheimer’s disease who remain unknown to the psychiatric in-patient services.
The evidence from several independent data sources indicate that such patients are 
rare and that the ascertainment method used was systematically unbiased in respect 
of the study’s findings (i.e. the method did not differentially ascertain older people 
or females with Alzheimer’s disease). I argue that limitations in epidemiological 
diagnostic criteria for Alzheimer’s disease are a greater potential source of error in 
the reported incidence rates rather than errors introduced by incomplete sampling. 
The incidence rate of the ‘broad’ classification of Alzheimer’s disease is more than 
double that of ‘probable’ disease. In addition, diagnostic criteria may differentially 
misclassify males and females with the illness. It is unlikely that a similar 
magnitude of people with Alzheimer’s disease have been underascertained.
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FUTURE RESEARCH
Progress in understanding the basic epidemiology of Alzheim er’s disease 
has been slow. To date, family history and age are the only conclusive risk factors 
that have been discovered in an illness that is older than human literature and affects 
over one quarter of people in their 80th decade. This thesis highlights the problem 
of accurate diagnosis in dementia research. Although the importance of using 
standard diagnostic criteria has been accepted, several have been proposed and aH 
remain in popular use! This prohibits a standard approach to the diagnosis of 
Alzheimer’s disease.
There is an error in the clinical diagnosis of Alzheimer’s disease which will 
remain until a unique pathognomonic feature or biological marker can be 
discovered. This source of bias confronts all epidemiological research in 
Alzheimer’s disease. Attempts to improve the diagnostic accuracy of clinical criteria 
are useful in reducing this source of bias but will never eliminate it. Diagnostic 
errors must always be considered as explanations of risk factor and disease 
association. To overcome criticisms of disease diagnosis, future research must 
recognise its importance and actively seek neuropathological verification of clinical 
diagnoses.
Fundamental facts about the epidemiology of Alzheimer’s disease are 
unknown and describing these should be major objectives of future research. 
Evaluation of geographical and temporal variation in health care provision and the 
effects of migration of people with Alzheimer’s disease must be studied. 
Comprehensive data on environmental toxins linked to this illness must be collected 
in defined geographical areas over a prolonged time period.
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Neither geographical nor temporal variation of incidence of any sub-type of 
dementia has been reliably demonstrated, even for categories (eg, alcoholic 
dementia) in which the environmental factor is beyond dispute. In the United 
Kingdom, there is a lack of information about the quality of the public water supply 
that can be used to assess exposure to environmental toxins within small 
geographical regions. Information on current concentrations of toxins in the 
environment is unsatisfactory since temporal changes over the prolonged 
asymptomatic period of the illness have probably taken place (eg, the effects of acid 
rain increasing aluminium leaching) (Pearce F, 1985). In addition,.the effects of 
population migration within this period cannot be ignored. People with dementia 
constitute a mobile population: the area in which they are living is not necessarily 
where the illness began.
There are many methodological issues in studying the epidemiology of 
Alzheimer’s disease. Some sources of bias cannot be overcome but can be 
quantified (the first part of this thesis is devoted to that of diagnostic error). 
Investigators have attempted to find modifiable environmental associations of 
Alzheimer's disease without first addressing the limitations of their study and have 
succeeded in causing controversy by raising more questions than answers. Public 
fears have been aroused without sufficient epidemiological evidence.
Alzheimer’s disease is an insidious disorder and definitive proof of 
environmental toxin causation will require a prospective epidemiological study in 
which the issues discussed have been addressed. This will be costly but there is no 
reason why risk factors for Alzheimer’s disease should be easier to discover than 
those of cerebro-vascular disease, ischaemic heart disease, colonic cancer, ete.
Epidemiological research cannot be separated from therapeutic and 
experimental research in Alzheimer’s disease (Figure 5). Councilling services must 
be planned with data on disease prevalence and natural history, hypotheses
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postulated by finding neurochemical deficits in demented people’s brains can be 
tested in therapeutic studies, genetic-epidemiological studies are needed to assess the 
population effect of isolating genes that cause Alzheimer’s disease in single family 
pedigrees, ete. Future research must appreciate the interdependence of these areas 
and a co-ordinated approach to research in Alzheimer’s disease is needed. 
Geneticists, molecular biologists, pharmacologists, epidemiologists and clinicians 
must work together. Does each not want to achieve the same goal?
What now?
In Scotland, ISD is a valuable data resource for further epidemiological 
research in Alzheimer’s disease. There is an opportunity to update the data base 
used in this thesis to provide a comprehensive national register of people with 
Alzheimer’s disease. This thesis has given original and important insights into the 
epidemiology of Alzheimer’s disease in Scotland. No cause or cure for 
Alzheimer’s disease has been described nor sought. The work needs to continue 
methodically. The population sample should be described from 1988 to present and 
geographical and temporal changes in disease incidence assessed.
Neuropathological verification of disease diagnosis must be a priority. Data on 
environmental toxins must be collected and the study sample followed prospectively 
to test aetiological hypothesis in an unbiased manner. There now exists in Scotland 
a unique opportunity to comprehensively study the epidemiology of Alzheimer’s 
disease.
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